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Abstract 
BCR-ABL+ acute lymphoblastic leukemia patients have transient responses to 
current therapies.  However, the fusion of BCR to ABL generates a potential 
leukemia-specific antigen that could be a target for immunotherapy.  To address 
how BCR-ABL+ leukemia escapes immune surveillance, we developed a peptide: 
MHC-II tetramer that labels endogenous BCR-ABL-specific CD4+ T cells.  Naïve 
mice harbored a small population of BCR-ABL-specific T cells that proliferated 
modestly upon immunization.  We saw that BCR-ABL specific T cells were cross-
reactive with an endogenous peptide derived from ABL.  Despite this cross-
reactivity, the remaining population of BCR-ABL reactive T cells proliferated upon 
immunization with the BCR-ABL fusion peptide and adjuvant.  In response to 
BCR-ABL+ leukemia, BCR-ABL specific T cells proliferated and converted into 
regulatory T cells (Treg cells), a process that was dependent on cross-reactivity 
with self-antigen, TGFβ1, and MHC-II antigen presentation by leukemic cells.  
Treg cells were critical for leukemia progression in C57Bl/6 mice, as transient 
Treg cell ablation led to extended survival of leukemic mice.  In an effort to find 
immunotherapy approaches for BCR-ABL+ B-ALL, we found that robust MHC-II 
expression, coupled with appropriate costimulation, correlated with lower 
leukemic burden.  We next assessed whether checkpoint blockade or therapeutic 
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vaccination could improve survival in mice with pre-established leukemia.  
Consistent with the low mutation load in our leukemia model, we found that 
checkpoint blockade alone had only modest effects on survival.  In contrast, 
robust heterologous vaccination with BAp peptide generated a small population 
of mice that survived long-term.  Checkpoint blockade strongly synergized with 
heterologous vaccination to enhance overall survival in mice with leukemia.  
Enhanced survival did not correlate with numbers of BAp:I-Ab-specific T cells, but 
rather with increased expression of IL10, IL17, and GrzmB and decreased 
expression of PD1 on these cells.  Thus, despite a paradigm in the field that 
numerous neo-antigen specific T cells are required for effective anti-cancer 
immunity, a rare cross-reactive CD4+ T cell population mediates anti-leukemia 
immunity in our model. 
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Chapter 1 An overview of interactions between cancer and T lymphocytes 
Introduction 
The focus of this thesis is to increase our understanding of the interactions 
between the immune system and cancer.  While the early studies of the immune 
system clarified that the immune system resided, by-and-large in the primary 
(bone marrow and thymus) and secondary (lymphatic) lymphoid organs, sporadic 
reports over the past thirty years have made it clear that immune cells are a 
major part of every tissue in the body (1-5).  Further, a new era of tools and ideas 
about immunology have fueled an examination of the immune system in 
diseases and tissues, which were not always thought to have an immune 
component (6-8).  In parallel with these discoveries in immunology, a new 
concept has developed in cancer biology; that cancers are comprised of tissue-
level organization (9-11). By that logic, I hypothesize that if cancers are tissues 
and tissues normally contain immune cells, there should be an immune cell 
component to all cancers-including leukemia.  Further, just as the immune cells 
in skeletal muscle tissue play a critical role in muscular pathologies (6), I 
hypothesize that the immune cells in “leukemia tissue” play a critical role in 
leukemia pathology.  I sought to test these fundamental hypotheses in my thesis.  
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Specifically, I sought to characterize if an immune “response” to leukemia 
existed, if this response was-at “baseline”-beneficial or detrimental to the host, 
and finally if this immune response could be modulated to improve therapeutic 
outcome of the host. 
Cancer: A complex disease with a genetic basis. 
Cancer has long been understood to initiate as a genetic disease, arising from 
mutations that lend a selective advantage to a cell (12, 13).  These mutations 
lead to pathologies associated with bulk size, metastasis, and/or secretion of 
toxic compounds.  Cancers have been recognized in humans since at least 
ancient Egyptian cultures, and therapeutic interventions for cancer have existed 
for just as long.  However, cancer was not a leading cause of death until recently.  
This industrial revolution led to a medical renaissance, particularly with the 
discovery and mass-production of penicillin and other antibiotics.  These 
treatment options led to an increased lifespan in humans, which allowed people 
to live long enough to die of cancer instead of other infections.  Thus, as the 
world became industrialized, cancer became a leading health problem.  By the 
1970’s the Nixon administration made cancer therapy a national effort.   
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Since cancer is a genetic disease that develops because of mutations, it seems 
plausible that these mutations could become therapeutic targets.  In fact, most 
cancers arise from multiple mutations.  Early evidence for this came from the 
studies of patients with Familial Adenomatous Polyposis (FAP), which results 
from autosomal dominant loss of one allele of the tumor suppressor APC (14).  
While this is mildly detrimental to FAP patients, loss of the second allele of APC 
occurs, which is the ‘second hit’ necessary to initiate transformation of colonic 
epithelia.  While most cancers clearly arise from multiple mutations, an argument 
exists that cancers may arise with one mutation.  BCR-ABL+ leukemia may 
sometimes be one such cancer.  While the chromosomal translocation BCR-ABL 
is a single mutation event, it leads to activation of multiple signaling cascades 
that together transform the normal cell into a malignant cell.  BCR-ABL is present 
in nearly all chronic myeloid leukemia (CML) in humans.  BCR-ABL is also 
present in a about 25% of B Acute Lymphoblastic leukemia (B-ALL) in humans, 
and this percentage positively correlates with the age of the patient population 
(BCR-ABL is more common in B-ALL of older adults than of younger adults). 
Despite early understanding of the genetic basis for cancer, this knowledge has 
not let to huge advances in treatment until recently, for which there are at least 
two main reasons: 1) the study of computational and molecular biology has made 
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huge progress, allowing scientists to better understand complex living systems; 
and 2) a fundamental change in our understanding of cancer: cancers are not 
just made up of the mutated “cancer cells”, but also a heterogeneous network of 
other cell types. 
 
The Cancer Stem Cell Theory Implies Immune Involvement in 
Malignancy 
Solid cancers are heterogeneous masses.  Histology makes it clear that a tumor 
is more than a single cell type.  One hypothesis for this heterogeneity is that, just 
as the heart has many different cell types from different lineages working 
together, a tumor also has many different cell types that work together for the 
function of the tumor.  The cancer stem cell theory suggests that a cancer stem 
cell can give rise to many different cancer cell types which help to form the tumor 
tissue (9).  Thus, the cancer stem cell theory supports the idea that a tumor 
contains cells that are not derived from the cancer stem cell, but were recruited 
to the tumor (implicitly, to support tumor progression).  Since immune cells are an 
important component of all other tissue types (1), the cancer stem cell theory 
implies that immune cells must be a component of tumors as well - and that the 
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immune cells that are recruited to a tumor should be beneficial for tumor 
progression.   
If there is a tissue stroma associated with a solid tumor like a melanoma, then 
there should be a tissue stroma associated with a liquid tumor like leukemia.  
However, it is less-clear how the “tumor stroma” in a leukemia would be defined, 
since the leukemia is ostensibly liquid and moving throughout the body.  
Leukemia: current treatments and knowledge gaps 
Leukemia is a broad group of pathologies 
The focus of my thesis research is modeling the immune response to leukemia. 
Leukemia is a broad name that means white cells in the blood.  Thus, leukemia is 
white blood cell cancer.  Most leukemias do surface in the blood, but they can 
arise in other site in the body such as the lymph nodes (15).  
While there are many types of leukemia, one way to categorize this disease is by 
the cell of origin.  By this classification, there are two main types of leukemia: 
leukemia arising from lymphocytes (lymphoid leukemia) and leukemia arising 
from myelocytes (myeloid leukemia).  Within these lineages, leukemias can be 
classified based on their activity.  There are chronic leukemias and acute 
leukemias, with chronic leukemias generally developing slower with a lower blast 
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percentage, while acute leukemias develop rapidly and have a high blast 
percentage (15).  Acute leukemia of lymphoid origin is referred to as Acute 
Lymphoblastic Leukemia, or ALL.   
Current therapies for ALL 
Most ALL cases are treated first by cytotoxic chemotherapeutics to achieve 
remission.  Remission is generally not durable, and patients often require a long-
term treatment solution.  For many patients, this long-term option is another 
round of chemotherapy followed by bone marrow transplant (16).  Despite these 
therapeutic interventions, long-term survival for adult ALL remains below fifty 
percent. 
Current ALL chemotherapies are derivatives of chemicals that were discovered in 
the past 150 years.  The industrial era of the late 1800’s and early 1900’s led to a 
renaissance in chemistry, with creation of massive chemical companies like 
Bayer and Pfizer.  While there were many industrial uses for the chemicals 
produced by these companies, the companies recognized the potential utility for 
their small molecules in exerting biological effects.  The chemical renaissance of 
the late 1800’s also led to the dawn of the era of chemical warfare around the 
time of World War I.  Critical observation by medical workers during and after 
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World War I noted that mustard gas victims had a pronounced leukopenia.  This 
early observation led to laboratory investigations into how these small molecules 
interacted with cancer, and it was found that these molecules could inhibit DNA 
fidelity and block replication in rapidly dividing cells like cancer cells.  
Chemotherapeutics based on mustard gas went on to become chlormethine, one 
of the first chemotherapeutics; and derivatives of these therapies are still used 
today (17, 18).   
The era of chemotherapy focused on targeting the cancer cell by identifying 
exquisitely small differences between the cancer cells and ‘normal’ cells in the 
body.  However, the therapeutic window for chemotherapies is very small, since 
there are minimal differences between a cancer cell and a normal cell.  In 
leukemia, there are a variety of clinical trials being conducted that explore 
cytotoxic chemotherapeutics to treat ALL.  Most of these therapies target cell 
division through various pathways, since cancer cells divide rapidly while most 
normal cells do not.  One regimen called hyper-CVAD (a course of 
cyclophosphamide, vincristine, and doxorubicin alternated with a course of 
dexamethasone and Ara-C) is used in some aggressive ALL cases, sometimes 
in combination with the tyrosine kinase inhibitor Gleevec (19).  Trials of hyper-
CVAD report side effects including hospitalization of the majority of patients, 
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fungal infection, pneumonia, sepsis, neurotoxicity, and disseminated 
intravascular coagulothapies, all with a long-term response rate of about 35% 
(20).  Thus, there has been a long-standing effort to identify other therapeutic 
modalities for cancer besides surgery and chemo/radiotherapy. 
 
Recently, a different long-term solution was found for a small family of leukemias 
called Chronic Myeloid Leukemia.  This long-term solution is maintenance 
therapy with one of a family of small molecules called tyrosine kinase inhibitors 
(TKI) (21-24).  This class of drug targets an enzyme family called tyrosine 
kinases, which are a component of cell signaling cascades.  Normal cells 
respond to growth signals from the extracellular matrix.  These growth signals 
often use tyrosine kinases to communicate the extracellular signals into changes 
in the normal cell.  In cancer cells, tyrosine kinases are often mutated so that 
they transmit signal even in the absence of extracellular growth signals.  Thus, 
the TKIs are designed to block the aberrant signaling that occurs through 
tyrosine kinases and by doing so, inhibit cancer progression.  Patients with CML 
often respond well to TKI treatment because the majority of CMLs express a 
chromosomal translocation that juxtaposes the Breakpoint Cluster Region gene 
(BCR) and the Src family kinase ABL.  This chromosomal translocation, termed 
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BCR-ABL is also expressed in about 25% of adult B-lineage ALLs (B-ALL) (25).  
Since BCR contains a docking site for GRB2 and ABL contains a tyrosine kinase 
domain, BCR-ABL may be able to rapidly activate the Ras and Akt signaling 
cascades (26).  Additionally, BCR-ABL can phosphorylate STAT5, which may 
lead to increased survival of transformed cells (27-30).  These signaling events 
can lead to transformation of the BCR-ABL+ cell.  The first major TKI was 
designed to specifically target the kinase domain of ABL in BCR-ABL.  This drug, 
Gleevec, is still used for induction in BCR-ABL+ B-ALL and CML, as well as 
maintenance therapy for BCR-ABL+ CML (26).   
Much of the work in this thesis discusses immune responses to BCR-ABL.  This 
may seem clinically paradoxical since BCR-ABL is already a well-established 
treatment target for TKIs as discussed above.  However, there are multiple 
reasons for our investigation of BCR-ABL as an immunotherapy target.  First, 
while BCR-ABL is present in nearly all CML, BCR-ABL is also present in a subset 
of Acute Lymphoblastic Leukemias (ALL) (23, 31), making BCR-ABL a relevant 
clinical target in ALL.  Second, resistance develops to BCR-ABL-targeted TKIs, 
particularly in BCR-ABL+ B-ALL.  Multiple mechanisms have been identified that 
lead to Gleevec resistance.  The most common (and that which is usually the 
case in Gleevec-resistant BCR-ABL+ CML) is acquisition of mutations in BCR-
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ABL that render Gleevec unable to bind the ATP binding pocket of BCR-ABL (32, 
33).   
The other mechanism of resistance is more specific to BCR-ABL+ B-ALL.  One of 
the targets of BCR-ABL kinase activity is STAT5 (28, 29).  Phosphorylated 
STAT5 (pSTAT5) in-turn leads to transcription of cell cycle progression genes 
such as Cyclin D1, Cyclin D2, and BclXL that lead to G1/S transition and evasion 
of apoptosis (34) (35).  B-ALL, but not CML, cells express large quantities of 
another transcription factor BCL6.  Multiple lines of evidence in a variety of cell 
types suggest that BCL6 and STAT5 reciprocally regulate one-another (36-40).  
Indeed, in BCR-ABL+ B-ALL cells, increased pSTAT5 inhibits BCL6, and 
increased BCL6 inhibits STAT5 transcription.  The Melnick group showed that 
when BCR-ABL+ B-ALL cells were treated with Gleevec, pSTAT5 levels 
decrease, allowing an over-accumulation of BCL6 (41).  BCL6 also drives a pro-
transformation transcriptional program (one mechanism of which may be to 
inhibit the tumor suppressor TP53 (42)) that then transforms the BCR-ABL+ B-
ALL cells through a STAT5-independent mechanism.   
New small molecule therapies are being developed that target Gleevec-resistant 
point mutants.  One such drug, Ponatinib, has had some clinical success, 
however the therapeutic window of this drug is relatively small (21). 
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Thus, there is a shortfall in treatment options for BCR-ABL+ B-ALL, and new 
therapeutic avenues should be explored. 
 
Treatment options for ALL: Surgery 
Surgery was the first treatment option used for cancer and is still a mainstay of 
cancer therapy today.  One problem with surgical therapy for cancer is that a 
requisite is being able to access most of the cancer cells.  In the case of 
leukemia, surgery is often not used, because there are not yet strategies to 
surgically debride leukemia from a patient.  An interesting dichotomy arises with 
ALLs regarding surgical therapy.  Specifically, B-ALL often arises as leukemia 
(blood cancer) while T-lineage ALL often presents as lymphoma (lymph node 
cancer) (15, 43).  Thus, T-ALL is generally easier to surgically resect, given the 
discreet location of lymph nodes, while B-ALL remains challenging to access in 
the blood. 
Treatment options for ALL: Targeting the Stroma 
Initial efforts for cancer therapy focused on targeting the cancer cell themselves.  
However, by the mid-1990s, it was clear that the tumor was a complex tissue-like 
structure.  Around this time, scientists started some of the first studies that 
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targeted a non-tumor cell type for improved therapeutic outcome in cancer 
(targeting vascular tissue in the tumor to prevent circulation and thus starve the 
tumor of nutrients) (44-46).  It has since become clear that the approach of 
targeting VEGF is not always ideal, as resistance mechanisms may be 
developed instead of preventing cancer progression (47).  Nonetheless, these 
types of therapies set a precedent for treating cancer by targeting cell types that 
were part of the tissue stroma of the tumor.  Just as the vasculature is part of that 
stroma, so are immune cells.  Thus, this precedent opened the door for cancer 
immunotherapy, by showing that, in some cases, there was a therapeutic benefit 
to targeting therapy to the tissue stroma of the tumor instead of to the cancerous 
cells themselves.  While endothelial cells that are the canonical target of VEGF 
support the tumor and this supportive action can theoretically be limited, immune 
cells in the tumor may be able to play a truly detrimental role to the tumor by 
actually killing tumor cells.  To that end, much work has gone into understanding 
the role of immune cells in solid tumors, particularly melanoma (48-50).  These 
findings have progressed into clinical trials and even first-line therapies in a few 
malignancies (51-53).   
Clearly, immune cells make up a component of tumors.  Methods to modulate the 
immune system to protect the host from cancer fall into five main categories: 
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adjuvants, vaccinations, bone marrow transplant, adoptive cell therapy, and 
inhibitory checkpoint blockade.  These methods will be detailed below.   
Adjuvants 
Immunological adjuvants were the first use of immunotherapy for cancer, and 
arose from straightforward clinical observations.  One striking story is from a 
Canadian physician named Hunter who describes a patient with a facial tumor.  
Shortly after this tumor diagnosis, the patient develops erysipelas at the tumor 
site.  Erysipelas is a cutaneous infection often with the bacteria Streptococcus 
pyogenes or Serratia marcescens.  In this case the infection produced a fluid-
filled abscess and the tumor was cleared shortly thereafter, allowing the patient 
to die of a heart attack some years later (54).  Around the same time as Dr. 
Hunter, a New York physician named William Coley’s was creating suspensions 
of heat-killed bacteria to inject into tumors (55).  For a time, the “Coley’s Toxins” 
were so popular that they were marketed by the pharmaceutical company Parke-
Davis.  However, the formulation proved challenging to correctly produce, and 
the treatment fell out of style with physicians and government regulators. 
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One hypothesis of how the Coley’s Toxins elicit their effect is as an adjuvant.  An 
immunological adjuvant helps to activate innate immune cells, which then allows 
for increased activation and programming of adaptive immune cells.  Adjuvants 
can be chemicals and other non-biological substances (for example, alum), or 
they may also be cytokines that may directly activate innate and adaptive 
immune cells.  One advantage of using cytokines instead of Coley’s Toxins is 
that Coley's Toxins are not well defined, while cytokines are individual proteins 
that can be purified to a pharmaceutical grade.  The downside is that a single 
cytokine may not provide the broad biological impact as Coley’s Toxins-due to 
the complex nature of Coley’s Toxins.  In part because of the defined nature of 
cytokines, these became the next step of immunotherapy.  Numerous clinical 
trials were conducted that treated cancer patients with cytokines like Type I 
Interferon (56) and IL-2.  Clinical trials were set up testing Type I Interferon in 
ALL patients, but ideal regimens are still being established. 
Adjuvants are still used in the clinic and in clinical trials, however their popularity 
is limited by the side effects associated with them.  However, one example that 
has made some clinical headway is the therapeutic vaccination ProstVac (57) 
(58).  ProstVac is a vaccinia virus-based vaccine that encodes antigens from 
prostate cancer as well as important immune costimulatory molecules (59).  
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Exactly how ProstVac modulates the immune response is not fully understood, 
but side effects have been relatively mild compared to standard chemotherapy 
(no patients died in the initial trials of ProstVac) (57).   
Vaccination 
Another approach for cancer immunotherapy is vaccination.  Immunology, as 
applied to medicine, has a long-standing tradition of vaccination.  Vaccination 
takes advantage of immunological memory-a component of the adaptive immune 
system.  The idea developed that vaccination could be used to activate adaptive 
immunity in response to cancer-and potentially this would be one mechanism of 
cancer immunotherapy.  The most famous “cancer vaccine”, Gardasil, does not 
actually target a cancer at all.  Instead, Gardasil targets a family of viruses that 
often are associated with cancer.  Thus, by preventing viral infection, Gardasil 
helps prevent cervical cancer.  Few other prophylactic vaccinations for cancer 
have been developed into full therapies, however the prophylactic vaccination 
still provides a useful “proof-of-principle” for the utility of a memory immune 
response against cancer. 
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Bone Marrow Transplant 
Cancers can adapt to the host immune system by inducing immune suppression 
(60-62).  This in-turn protects the cancer from the host immune response (63, 
64).  Because of this base-level immune suppression, immune cells in the 
cancerous host often have minimal effect on the tumor.  While some therapies 
aim to reprogram these host immune cells to increase functionality, other 
therapies look to place new, functional, immune cells into the host, such that 
these might be programmed to effectively control cancer (65).  The basis of this 
is bone marrow transplant.  Bone marrow transplant is a therapy for many 
diseases.  In some cases, the idea with bone marrow transplant is to match the 
donor and host bone marrow as close as possible.  This is ideal for minimizing 
the autoimmune side effects, which can occur from bone marrow transplants.  
However, in the case of cancer treatment, physicians aim to slightly mismatch 
donor and host bone marrow.  This allows the donor-derived adaptive immune 
cells to recognize host cells as “non-self”.  This can then lead to the donor-
derived adaptive immune cells killing the host cancer cells.  This effect is referred 
to as “Graft-vs. -Leukemia” or GVL.  The benefit of GVL is weighed against the 
detriment of “Graft-vs. -Host” (GVH) which is the broad term for autoimmune 
complications arising from bone marrow transplant.   
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Adoptive Cell Therapy 
Instead of transferring fresh immune cells into a cancer host by bone marrow 
transplant, another approach is to reprogram the host’s immune cells ex vivo, 
followed by adoptive transfer of these cells back into the host (66).  Such 
therapies are referred to as “Adoptive Cell Therapy” or ACT.  The basic concept 
is to harvest immune cells from a patient with cancer and culture these cells in a 
dish ex vivo with the correct signals so that the cells become highly activated and 
programmed to control cancer progression.  These cells are allowed to proliferate 
many times, and then the cells are adoptively transferred back into the host.  This 
therapy option has proven effective in clinical trials (66, 67).   
Immune Inhibitory Checkpoint Blockade 
Instead of harvesting the immune cells from a patient and culturing them ex vivo, 
the main area of research and clinical application currently is using approaches 
to re-activate immune cells inside of the cancer host.  This greatly increases the 
therapeutic window and decreases the side effects, since no cells are transferred 
(a major infection risk that also requires aggressive immunosuppression).  
Instead, this approach uses antibodies that specifically bind to, and block, 
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molecules that normally inhibit an immune response(49, 68-72).  Such molecules 
(like PDL1 and CTLA4) are often expressed at high levels on tumor cells, and 
likely help the tumor to control and modulate the immune cells in the tumor 
stroma.   
Cancer and the Immune System 
The evidence showing that infections correlated with improved outcome to 
cancer was fortified by causative evidence in humans in the past few years that 
linked immune status to cancer progression (51).  These findings came from 
clinical trials examining checkpoint blockade therapies that showed immune 
modulation could lead to improved outcome for some cancers. 
T cells in Cancer 
Of all the immune cells, T cells are probably the most studied in relation to 
cancer.  T cells are hematopoietic cells that develop further in the thymus.  
During thymic development, T cells are engendered with a T cell receptor (TCR) 
which recognizes cognate antigen in the context of a Major Histocompatibility 
Complex (MHC).  TCR development occurs in a sufficiently random process that 
T cells should be engendered with individual TCRs capable of recognizing nearly 
any possible amino acid sequence bound to MHC.  Most T cells recognize 
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foreign antigens.  Since cancer derives from cells that are normally in the body, 
most proteins expressed by cancers are not foreign antigens but instead are 
‘self-antigens’.  This presents a problem for T cell mediated cancer 
immunotherapy.  However, the rules of ‘self’ and ‘foreign’ are not clearly defined, 
and this provides some wiggle-room for T cell based cancer immunotherapy. 
T cell development and central tolerance 
Because T cells can have a highly destructive capability, thymic development 
has also evolved to remove most T cell clones that recognize self-peptides 
bound to MHC (termed central tolerance).  The processes enabling central 
tolerance are still being understood, but part of this process involves signaling to 
T cells that cross-react with self, such that a pro-apoptotic protein called Bim is 
activated in these cross-reactive T cells (73).  Bim leads to activation of intrinsic 
apoptosis mechanisms, which destroys the cross-reactive T cell.  Indeed, Bim-/- 
mice have increased abundance of T cells, with enrichment of cross-reactive 
clones (63, 74, 75).   
CD4+ T cells in cancer 
Some T cells express the co-receptor CD4, allowing these T cells to utilize the 
TCR to recognize antigen presented in the context of MHC-II (p: MHC-II).  In 
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addition to differences in the structure of MHC-I vs. MHC-II, the other major 
difference is where and when MHC-II is expressed as compared to MHC-I.  
While MHC-I is expressed on essentially every cell in the body, MHC-II is 
canonically expressed on “professional” Antigen Presenting Cells (APC), which 
are cells specifically differentiated to process and present antigen (mainly B cells, 
macrophages and dendritic cells).  Therefore, CD4+ T cells normally only 
recognize antigen presented by these cell types.  This is with the caveat that 
MHC-II expression can be induced on other cell types, often by IFNγ.   
CD4+ T cells are classically called “T-helper” cells, and the nomenclature 
commonly delineates subsets of CD4+ T cells as “Thx”.  The role of T helper cells 
often is to “Help” the immune response-that is modulate it in various ways.  A few 
examples of what ‘help’ may manifest as include activating CD8+ T cells and 
improving antigen presentation (the job of Th1 cells), inducing neutrophil and 
granulocyte activation (Th17 cells), or slowing down CD8+ T cell function and 
antigen presentation (Treg cells).  These T-helper subsets are commonly 
classified based on the abundance of certain transcription factors (TBET for Th1, 
RORGT for Th17, FOXP3 for Treg, etc.) and cytokine production (IFNγ for Th1, 
IL17 for Th17, and TGFβ for Treg, etc.) Given the broad range of potential 
functions of CD4+ T cells, these cells can potentially be beneficial or detrimental 
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to a host organism as it’s immune system responds to the pathogen insult of 
cancer.  
Th1 cells are the first lineage of T cell discovered, by Tim Mossman in the mid 
1980’s (76).  Because of the cytokines produced by Th1 cells, these cells are 
important for clearing intracellular pathogens by inducing macrophage activation 
(77-79), for inducing B cell class switching to IgG (80) and for helping CD8+ T 
cells respond to infections (81).  In coordination with expression of the 
transcription factor Tbet (82), Th1 cells are classically thought to produce IFN-
gamma, interleukin-2 (IL2) and TNF-alpha, though they are described as 
producing a host of other cytokines in response to various stimuli (83). 
 
Tregs are CD4+ T cells that express the transcription factor FOXP3.  These cells 
canonically have an immune-suppressive function, which may manifest in a 
variety of mechanisms.  Recent literature supports that Tregs can induce 
immune-suppression by secreting anti-inflammatory cytokines (63, 84), 
reprogramming antigen presenting cells (APC) to an immune-suppressive 
phenotype, internalizing cytokines required for T cell activation, contact-
dependent inhibition of effector cells by a Granzyme B-mediated mechanism 
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(85), and secreting molecules that dampen metabolism of surrounding immune 
cells.  In normal circumstances, Tregs are a necessary part of maintaining 
immune homeostasis in the body.  Evidence for the necessity of Tregs comes 
from humans and mice with genetic ablations of FOXP3, which leads to a body-
wide autoimmune syndrome called immunodysregulation polyendocrinopathy 
enteropathy X-linked syndrome (IPEX) (86-89).  Tregs may also play a critical 
role in suppressing the immune response at the end of an infection, and also in 
maintaining equilibrium with commensal organisms.  In the context of cancer, 
Tregs generally are thought to be detrimental to the host and advantageous for 
cancer progression.  A positive correlation between Tregs and tumor progression 
has been suggested (90).  Interestingly, the role of Tregs varies depending on 
the type of tumor model used.  For example, Tregs appear to be required for 
cancer progression in one orthotopic breast cancer model and our own studies of 
BCR-ABL+ B-ALL (63, 64), but Tregs do not play as fundamental of a role in an 
acute myeloid leukemia model (62).  
 
Th17 cells are a recently discovered lineage of cell that is critical for recruitment 
and activation of granulocytes (91, 92).  The role of Th17 cells in tumors is 
somewhat controversial and may be highly dependent on the tumor type.  
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However, there is firm evidence in mice supporting either a benefit or a detriment 
for Th17 cells in tumors of various types (93-96). 
 
Another recently described lineage of T helper cell is the cytolytic (TCL) cell.  
These cells are purported to directly kill target cells through Granzyme/perforin or 
Fas-mediated mechanisms (83, 97).  This lineage of CD4+ T cell is thought to 
lyse target cells in a p: MHC-II dependent manner.  This lineage is theoretically 
important since many B lineage leukemic cells express MHC-II, and thus could 
potentially be targets for lysing by TCL cells.  These cells are generally 
characterized by expression of Granzyme B, Perforin, and Fas signaling 
components(83). 
Studying T cells in Cancer Immunotherapy 
T cells are a major arm of adaptive immunity, and their function in response to 
many pathogen insults including cancer-has been well characterized.  However, 
the vast majority of studies that examine T cell responses examine the bulk CD4+ 
or CD8+ T cell response.  This is because technology was only available in the 
past 30 years to examine antigen-specific T cell responses to a peptide: MHC 
complex (98-100).  The advent of molecular cloning of TCRs, and then TCR 
  24 
transgenic mice allowed investigators to interrogate an antigen-specific immune 
response by adoptive transfer of TCR transgenic T cells into mice, followed by 
challenge with the pathogen of interest.  This approach still had drawbacks, as 
these transferred T cells were a monoclonal population (all T cells had exactly 
the same TCR, and thus responded in a monoclonal response).  To examine the 
polyclonal T cell response to a pathogen insult required another technological 
breakthrough.  By the mid 1990’s, a number of crystal structures of p: MHC-I 
combinations had been solved, and there was an understanding of certain 
pathogen peptides that bound to MHC-I.  This information was used to generate 
a p: MHC-I labeled with biotin, which could then be attached to Streptavidin 
linked to a fluorochrome.  These so-called p: MHC “tetramers” (a reference to the 
4-sided tetrameric assembly of p: MHC’s on the streptavidin) allowed labeling of 
endogenous T cells engendered with a TCR that bound to the labeled p: MHC-I 
(101).  This breakthrough technology allowed investigators to use conventional 
flow cytometry to analyze CD8+ T cells as they responded to cognate p: MHC-I in 
vivo and thus gain a highly detailed level of understanding of the immune 
response (102).   
The p: MHC tetramer was a major breakthrough because it allowed investigators 
the resolution necessary to discern and directly enumerate distinct antigen-
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specific T cells.  Simply examining bulk activated T cells in response to a given 
pathogen was not sufficient, since even Specific Pathogen-Free mice could be 
responding to many pathogen insults at a given time.  So understanding which in 
vivo responses were due to the pathogen of interest, and which were due to 
other peptide: MHC encountered by the T cells was impossible prior to the p: 
MHC tetramer. 
In the late 1990’s to early 2000’s, similar technology was developed to 
interrogate CD4+ T cells by using p: MHC-II tetramers.  This technology 
potentially allowed for in vivo labeling of antigen-specific CD4+ T cells.  However, 
a biological hurdle associated with how peptides bind to MHC-II limits the 
feasibility of p: MHC-II tetramers for any given peptide.  While MHC-I binds to 
peptides with a binding cleft that is “closed” on the ends (thus allowing only ~9-11 
amino acids to bind the MHC-I), MHC-II has an “open” binding cleft, where 
potentially very long peptides might bind MHC-II.  This means that computational 
algorithms based strictly on interaction of amino acids with the MHC-II binding 
cleft may not be useful since binding points outside of the binding cleft may be 
important for a given peptide: MHC-II interaction.  Because of this drawback, 
there is a relative paucity in understanding the role of CD4+ T cell responses to 
pathogen insults.  For example, to the best of our knowledge, our study is the 
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first to characterize a leukemia-reactive CD4+ T cell population responding to 
leukemia in vivo. 
Conclusions  
Cancer is now understood to comprise an entire tissue, with its own vasculature, 
stroma, and immune features.  While many studies have examined the role of 
exogenous T cells to interact with the tumor (via adoptive transfer), there is scant 
understanding of how the endogenous T cells interact with the tumor.  Cancer 
has an amazing capacity to undergo natural selection.  Cancer cells have a 
highly unstable genome, and this allows many rounds of mutation to achieve a 
desired outcome.  As such, it seems clear that a cancer should be able to 
acquire mutations that render it a favorable advantage over the immune system.  
A main focus of this thesis is to examine cancer and immunology with an 
appreciation for the capacity of the tumor to have selective advantages.  As such, 
a common idea that I am exploring in this thesis is that, just as a tumor requires 
vascular stromal tissue to maintain the life of the tumor, maybe the tumor also 
requires immune cells for survival.  Perhaps, at steady state, the immune 
response to a tumor is fully beneficial to the tumor. 
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Chapter 2 Tracking BCR-ABL specific CD4+ T cells during steady state and 
responding to leukemia 
Introduction   
1Cancer immunotherapy is an effective clinical approach in malignancies with 
high rates of non-synonymous mutations (52, 103-105).  Most cancer 
immunotherapy approaches currently focus on neo-antigen specific T cells, 
which ideally respond to mutations in proteins that drive tumorigenesis (69, 106-
108).  However, identifying non-synonymous immunogenic mutations in driver 
                                            
 
 
1 The majority of Chapter 2 is previously published. 
 
63. Manlove, L. S., Berquam-Vrieze, K.E., Pauken, K.E., Williams, R.T., 
Jenkins, M.K., Farrar, M.A. 2015. Adaptive immunity to leukemia is inhibited by 
cross-reactive induced regulatory T cells. The Journal of Immunology. 
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genes is not always possible, thereby necessitating the use of either multiple 
antigens, or cross-reactive self-antigens, to prevent immune escape.  This 
problem is illustrated in B cell acute lymphoblastic leukemia (B-ALL), which has 
few non-synonymous mutations (109).  However, B-ALL is characterized by 
chromosomal translocations that give rise to fusion proteins encoding neo-
antigens that drive transformation (31).  We focused on BCR-ABL+ B-ALL, which 
creates a neo-antigen at the fusion of BCR to ABL.  Immunotherapy is an 
attractive goal in BCR-ABL+ B-ALL because current therapies elicit only transient 
responses and long-term survival is poor. CD4+ T cells from patients with BCR-
ABL+ B-ALL can secrete IFNγ upon ex vivo restimulation with peptides from the 
BCR-ABL fusion, but these responses are inadequate to eradicate leukemia in 
vivo (110, 111).  To understand why BCR-ABL specific immunity fails to eliminate 
BCR-ABL+ B-ALL in mice, we identified BCR-ABL specific CD4+ T cells and 
tracked their responses to leukemia in vivo. 
 
To examine anti-leukemia T cell responses we made use of a BCR-ABL+ B-ALL 
mouse model that recapitulates the human disease (112).  To track anti-leukemia 
T cell responses, we generated a BCR-ABL peptide (BAp): MHC Class II 
tetramer reagent.  We demonstrate that an adaptive immune response is elicited 
  29 
against BCR-ABL+ B-ALL and this response limits leukemia progression.  BAp:I-
Ab-specific T cells exist in mice and proliferate in response to immunization with 
BAp peptide plus an adjuvant.  Inoculation with live BCR-ABL+ leukemic cells 
also resulted in proliferation of BAp:I-Ab-specific T cells.  However, these cells 
were converted into Treg cells and thus unable to eliminate leukemia.  
Importantly, transient Treg ablation with Foxp3DTR/DTR mice resulted in extended 
lifespan of leukemic mice, which correlated with increased number of CD44hi, 
Ly6C+ BAp:I-Ab-specific T cells, suggesting that induction of Treg cells by the 
leukemia led to decreased priming and Th1-like CD4+ T cell differentiation.  
 Materials and Methods 
Mice 
C57BL/6 mice and Cdkn2a-/-  (strain 01XF6, B6, 129-Cdkn2atm1Cjs/Nci, (113)) 
mice came from the National Cancer Institute.  Foxp3-GFP (stock# 006772) mice 
came from Jackson Laboratories (Bar Harbor, ME).  Bim-/-, OT-IxRag2-/-, 
Foxp3DTR/DTR, OT-IIxRag2-/- and SM1xRag2-/- mice were generated locally as 
previously described (75, 98, 114-116).  Mice were housed at the University of 
Minnesota in specific pathogen free conditions and all experiments were 
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approved by IACUC. Statb5CA transgenic mice were previously described and 
have been maintained by our lab (117). 
 
Immunizations 
Mice were immunized with Complete Freund’s Adjuvant (CFA)+BAp 
subcutaneously in the hind flank.   
 
Anti-TGFβ in vivo treatment 
Mice were treated with anti-TGFβ (clone 1D11, Bio X Cell) or isotype (clone 
MOPC21, Bio X Cell) with 1mg i.p. on the same day that the mice were 
inoculated with leukemia, followed by 200µg i.p. every-other-day for fourteen 
days. 
Anti-IL10R in vivo treatment 
Mice were treated with anti-IL10R (clone 1B1.3A, Bio X Cell) or isotype (clone 
HRPN, Bio X Cell) with 0.3mg i.p. every-third-day. 
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Diphtheria Toxin Treatment 
Mice were treated with 0.2µg/mouse diphtheria toxin (List Biologicals) by i.p. 
injection every-other-day unless otherwise described in figure legends.  Treg 
depletion was analyzed by monitoring GFP+, CD4+ cells. 
 
Leukemia model  
The BCR-ABL+ B Acute Lymphoblastic Leukemia model has been previously 
described (118).  Briefly, Cdkn2a-/- mouse bone marrow cells were transduced 
with viral supernatant containing a BCR-ABL (P190)-IRES-GFP retrovirus (119).  
Cells were cultured in RPMI1640+10%FBS+1%Penicillin-Streptomycin+1%L-
Glutamine+0.001%beta-mercaptoethanol in a 37°C incubator.  2,500 live cells 
were adoptively transferred i.v., into host mice without prior irradiation.  The SP1 
cells were derived from leukemia in a STAT5bCAxPax5+/- mouse as previously 
described (120).  MHC-II-/- leukemia was generated by crossing Arf-/- mice with I-
Ab-/- mice to generate Arf-/-, I-Ab-/- mice.  Bone marrow from this genotype was 
transduced with the BCR-ABL IRES GFP retrovirus to generate MHC-II-/-, BCR-
ABL+ GFP+ leukemic cells. 
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Tetramer production 
The BAp:I-Ab tetramer and others used herein were produced as described 
(121).  Purified monomer was tetramerized with SA-PE or SA-APC.  
Tetramerization was conducted as described below with an example: 
1) Convert concentration of monomer from mg/mL to mM.  Divide concentration 
by 0.066, for instance, 3.529 mg/mL/0.066=49.38 mM.   
Sample calculation: C1V1 monomer=C1V1 SA-PE 
(49.38 mM)(X)=(9.5 mM[SA])(50 ml)  when 9.5 mM[SA] and 7 mM[PE] (but this 
varies from vial to vial) 
2) X=9.61ul, but because we want 4 monomers for every molecule of SA, we 
multiply 9.61 by 4.5 to ensure saturation. 
3) 9.61x4.5= 43.28 
4) 43.28+50ml SA-PE= 93.28 ml total.  Spec this mixture to determine the 
molarity of PE (choose fluorescence on the spec instead of protein) 
5) Use this molarity for the next calculation (example: 3.8 mM) 
6) (3.8 mM [PE])=(9.5 mM[SA])/7mM [PE])=5.15 mM[SA] 
7) (5.15 mM[SA])(93.3 ml)=(1mM)(X)    X=480.495 
8) 480.495ml - 93.3 ml = 387.195 ml 
9) Add 387.195 ml PBS-A to the tube to obtain a 1 mM concentration of tetramer 
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Antigen-Specific CD4+ T cell Enrichment Strategy  
I-Ab tetramer-binding cell enrichment was performed as described (121). 
Tetramers loaded with PE and APC were used together, and tetramer double-
positive events were analyzed to increase sensitivity and specificity (122).  Cells 
were enriched with either Miltenyi or StemCell anti-APC and anti-PE reagents 
following manufacturer’s protocols.  The enriched fractions were mixed with 
Accucheck counting beads (LifeTechnologies, Grand Island NY) for cell 
enumeration. The following procedure details the enrichment strategy for 
StemCell kits, which is what was used most of the time. 
Buffers: 
“Sorter Buffer” 
 0.5% Serum 
 1x phosphate-buffered saline (Dulbecco’s) 
*all flow analysis will also be run in this buffer.  These enrichments tend to leave 
quite a few dead/dying/sticky cells.  Running in very low concentrations 
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1) Sacrifice the mice with cervical dislocation/CO2 in WMBB 2-240 
2) Spray the outside of the mouse with 70% EtOH 
3) Open the mouse with a midline dermal incision, leaving the peritoneum intact 
4) Use manual force to extend the incision circumferentially about the midline of 
the mouse 
5) gently pull the skin down and up, to deglove the mouse 
6) Excise the inguinal, axillary, brachial, superficial cervical, submandibular, 
mesenteric, and para-aortic lymph nodes, as well as the spleen(SLO). 
7) Place all Secondary Lymphoid Organs into 1 well of a 6 well plate filled with 
1mL ice-cold sorter buffer.  Cells should be on ice for the rest of procedure, 
unless otherwise stated. 
8) Deglove any remaining skin on the 2 hind legs. 
9) Use snips to sever the femur immediately distal to the iliac joint. 
10) Use snips and Kim wipes to clear excess tissue from the long bones. 
11) Load a 5mL syringe with a 26ga needle.  Aspirate 2mL of ice-cold sorter 
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buffer through the long bone lumen using the syringe.  Repeat for femurs, tibias, 
and fibulas. 
12) Cut small squares (~1cm x 1cm) of 70um mesh netting. 
13) Use forceps to place the square in the center of the bottom of the well of the 
6-well plate.  Use forceps to pile all Secondary Lymphoid Organs on top of the 
mesh.  Use the plunger of a 5mL syringe to mash the Secondary Lymphoid 
Organs through the 70um mesh square.   
14) Move all tissue/liquid 15mL polypropylene conical tube. 
15) Rinse mesh in the 6 well plates w/ another 2mL sorter buffer.  Then, do 
another mash + rinse.  We want to make absolutely sure we recover all cells at 
this step.  Top off the conical w/ sorter buffer and spin down 1600rpm 5min 4C in 
enclosed BSL-2 containers. 
16) Aspirate liquid into bleach-prefilled vacuum flasks with secondary 
containment 
17) add Fc block (clone 2.4G2 Serum Free Media + 2%mouse serum + 2% rat 
serum) to a final volume of 2x the pellet itself-using the gradations in the 15mL 
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conical to guide you.  So if your pellet is about 200uL, then add another 200uL of 
sorter buffer. 
18) resuspend the pellet by vigorously sliding the 15mL conical over a 15mL tube 
rack. 
19) Add tetramer to the sample at a final concentration of ~10nM , depending on 
the dose response curve for the current lot of tetramer.  The tetramer should say 
what its concentration is.  For 2W1S:IAb, it seems to be at 1uM (i.e. 1000nM) 
usually, so a 1:100dilution of tetramer into Fc block /cell pellet should suffice.   
-so, if you have 200uL pellet, then add 200uL Fc Block + 4uL Tetramer. 
20) Vortex and incubate for 1 hour at room temperature in the dark. 
21) Wash with 15mL cold sorter buffer at 1600rpm 5min 4C in enclosed BSL-2 
centrifuge.   
22) Aspirate liquid into a bleach-prefilled vacuum flask with secondary 
containment and add 1mL sorter buffer to the pellet.   
23) Vigorously slide the tubes over a 15mL tube rack to resuspend. 
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24) Add 15uL StemCell PE selection cocktail + 15uL StemCell APC selection 
cocktail 
25) Vortex quickly and incubate room temperature for 15 minutes in the dark. 
26) Set up StemCell magnets at room temperature 
27) add 45uL StemCell enrichment beads to each pellet (they should still be at 
~1mL volume) 
28) incubate 10 min at room temperature in the dark. 
29) Add 1mL ice cold sorter buffer to each tube (the total volume should now 
approximate 2.5mL, which is the optimal volume for loading onto the StemCell 
magnet) 
30) Put a piece of 70um nylon mesh on top of a FACS tube 
31) cut the last ~4mm off of a p1000 tip (the goal is to widen the bore just slightly) 
and set a p1000 to ~800uL.  
32) Use the pipet to gently resuspend the cells/2.5mL liquid.  
33) Aspirate the cells into the FACS tube through the 70um mesh.  Be aware, it 
may take multiple pieces of 70um mesh to aspirate all the liquid into the FACS 
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tube, since these will get clogged quickly.  If they get clogged, just throw out that 
piece of mesh and get a new one. 
34) Put the FACS tubes on the magnet for 5min room temperature 
35) Either tip the StemCell magnet rack so that the FACS tubes empty into 15mL 
conical tubes, or manually decant the FACS tubes into 15mL conical tubes. 
36) Add 2.5mL sorter buffer to the FACS tube and return to the magnet (if it was 
ever removed from the magnet-it’s fine to remove or not remove the FACS tube 
from the magnet after decanting, but make sure the FACS tube is in the magnet 
while decanting!) 
37) incubate for 5min room temperature and decant as above.  Repeat one 
more time after this for a total of 3x 
38) After 3 washes (thus leaving you with a total of 7.5mL decanted liquid), 
evaluate the FACS tube and make an executive decision about if more washes 
may be needed.  They will help increase your enrichment efficiency at the 
expense of time and cell viability. 
39) equalize volumes in the 15mL conicals w/ sorter buffer and spin down in an 
enclosed BSL-2 centrifuge. 
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40) Add 50uL of antibody cocktail to the cell pellets (I normally take (40uL x # of 
samples *0.10) + (40uL x # of samples) = volume of sorter buffer; plus 1.1uL of 
each antibody/sample.  A normal panel might be: 
APC: Tetramer (already stained) 
PE: Tetramer (already stained) 
BV421: CD25 (PC61) 
BV510: CD19 (1D3)/CD69 
BV650: CD45.1/CD8a (55-6.7) 
BV785: CD44 (IM7) 
PECy7: Ly6C 
PerCPCy5.5: CD4 (RM4/5) 
APCef780:  
 NK1.1 
 CD11B 
 CD11C 
  40 
 CD45.1 
 B220 
 F4/80 
FITC: PD1 (J43) 
-I would be cautious running over 10 colors, particularly if fix-perming.  [As will all 
F.C.] the analysis seems to run cleaner when less compensation is involved.  
The catch here is that the event number may bee exceedingly low, so I wouldn’t 
want to mis-report because of a weird F.C. error.  
41) Incubate on ice 30min dark. 
42) Wash samples w/ 3mL sorter buffer in enclosed BSL-2 centrifuge 
43) Aspirate the supernatant into a bleach-prefilled vacuum flask with secondary 
catchment and resuspend in 600uL sorter Buffer + 100uL Counting beads in a 
FACS tube (i.e. 12 x 75mm polystyrene tube). 
44) Move the samples to the flow cytometry core facility to analyze. Make sure to 
run bleach through the cytometer upon finishing, followed by water.  As well, the 
waste tank for the cytometer must be bleach-prefilled. 
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45) Clean up by scrubbing tools with hot water, Bac-Down soap, and 1:1000 
bleach.  Make sure to rinse the tools vigorously to remove bleach. 
46) Mouse carcasses need to be closed into airtight bags and returned to the 
BSL-2 cooler in WMBB 1-514 if BSL-2 experiments. 
47) All exposed consumable wastes should be double-bagged in autoclave bags 
and sterilized by autoclaving. 
48) All liquid waste should soak for >20 minutes with bleach, and then can be 
washed down the sink drain with excess water. 
 
Intravenous (i.v.) labeling 
I.v. labeling was performed using 15µg anti-CD45.1 antibody conjugated to 
PerCP-Cy5.5 (eBioscience).  Antibody was suspended in 200µL PBS and the 
mixture was injected by tailvein i.v. injection.  Three minutes later, mice were 
euthanized and SLO was harvested. 
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Histology 
Histology was performed as previously described and antibodies are listed below 
(123).  A brief protocol is detail below for most staining conditions.   
1. Fix slides in Acetone (-20 C) for 10 minutes. Allow to air dry ~5 minutes 
2. Apply PAP Hydrophobic Pen around the edges of the slides.  Allow drying for 
3-5 minutes 
3. Rehydrate slides in PBS.  Sections will need up to 500µL of PBS for complete 
coverage.  NOTE:  After this step, DO NOT allow the slides to dry out.  This 
will compromise ability to image the slide. 
4. Blocking Solution: Apply 200 uL of 5% BSA PBS solution.  Place in humidified 
chamber for 45 minutes to one hour. 
5. Add primary antibody stain mixture to slides (in PBS - volume of 150 uL).  
Stain for 60 minutes. 
FITC/AF488: Goat anti-GFP (probably 1:100 is good) 
PE/AF555: 
APC/AF647: rat anti-Foxp3 (1:100, clone FJK16S) 
UV/DAPI:  
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6 Wash slides 3x in PBS.  Apply 200 uL of PBS to wash.  Let sit for 1-3 minutes 
after each application of PBS. 
7. Add secondary antibody stain mixture to slides (in PBS - volume of 150 uL) for 
60 mins 
FITC/AF488: Bovine anti-goat AF488 (1:200) 
PE/AF555: 
APC/AF647: donkey anti-rat AF647 
UV/DAPI:  
8. Wash slides 2x in PBS.  Apply 200 uL of PBS to wash.  Let sit for 1-3 minutes 
after each application of PBS. 
9. Incubate slides with 200 uL of 5% rat serum in PBS for 20 minutes. 
10. Add other antibodies - in this case CD3 PE (5% rat serum in PBS - volume of 
150 uL) for 60 mins (quick spin CD3 down to remove deconjugated PE.) 
FITC/AF488:  
PE/AF555: Hamster anti-mm CD3 (1:100, 145-2C11 clone) 
APC/AF647:  
UV/DAPI: Rat anti-mm/hs B220 (BV421) (1:100) 
11. Wash slides 3x in PBS.  Apply 200 uL of PBS to wash.  Let sit for 1-3 minutes 
after each application of PBS. 
12. Apply 40 uL of prolong gold per slide (20 uL per section).  Apply coverslip. 
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Antibodies 
Antibodies for flow cytometry and histology include CD3 PE, CD4 (RM4-5) 
PerCPCy5.5, CD8 (53-6.7) BV650, CD11c (N418) PE, FOXP3 (FJK16S) PE, 
were purchased from BD Biosciences (San Jose, CA); NK1.1 (PK136), CD11b 
(M1/70), CD11c (N418), B220 (RA3-6B2), and F4/80 in APC-eFluor780; PD1 
(J43) FITC, CD73 eFluor450, FR4 PE-Cy7, PDL1 PerCP-eFluor710, MHC-II I-Ab 
eFluor450, IL7R PE, and all ELISpot antibodies were purchased from 
eBiosciences (San Diego, CA), and IgM (Fab’) APC was purchased from 
Jackson Immunoresearch (West Grove, PA).  Rat IgG1 (HRPN) PerCP-Cy5.5 
Isotype and Rat IgG2a (2A3) violetFluor450 Isotype were purchased from Tonbo 
Biosciences (San Diego, CA).  Cells from enriched fractions were analyzed on an 
LSR-II Fortessa cytometer (BD Biosciences, San Jose CA) and data was 
analyzed in FlowJo (Treestar, Ashland OR).  Intracellular cytokine staining was 
done using BD Cytofix/Cytoperm reagents and protocols (BD Biosciences, San 
Jose CA).  Anti-IL10 (JES5-16E3, PE, eBiosciences), TGFB1(LAP) (TW7-16B4, 
ef710, eBiosciences), IFNγ (XMG1.2, BV421, BD Horizon), and TNFα (MP6-
XT22, AF488, eBiosciences) were stained by this procedure. 
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ELISPOT 
C57BL/6 mice were immunized with e1a2 peptide 
(GEGAFHGDAEALQRPVASDF, 2 mg/ml) or 2W1S peptide 
(EAWGALANWAVDSA, 0.2 mg/ml) emulsified in Complete Freund’s Adjuvant 
(CFA) (Sigma-Aldrich, St. Louis, MO) and harvested two weeks later.  CD4+ T 
cells were enriched using a mouse CD4 T cell Isolation Kit (Miltenyi, Bergisch 
Gladbach Germany).  Naïve mouse splenocytes were harvested, irradiated and 
mixed at a 1:1 ratio with the immunized CD4+ T cells in wells coated with IFN-
gamma capture antibody (AN-18) at a concentration of 15mg/mL.  Synthetic 
overlapping peptides that spanned the BCR-ABL p190 fusion (Genscript, 
Piscataway, NJ) were added to individual wells.  2W1S peptide and 
Concanavalin A were used as positive controls.  Samples were developed using 
a biotinylated IFN-gamma detection antibody (R4-6A2) and streptavidin-Alkaline 
Phosphatase with 5-Bromo-4-chloro-3’-indolyphosphate (BCIP) and Nitro-blue 
tetrazolium (NBT) developing agents and photographed and analyzed with a 
ImmunoSpot S6 Microanalyzer using the ImmunoCapture 6.3 and ImmunoSpot 
5.0 Pro DC software (Cellular Technology Ltd. (Shaker Heights, OH). 
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Statistics 
Standard normality tests suggested departures from normality, so non-parametric 
tests (Mann-U Whitney test for two groups, Kruskal-Wallace & Dunns’ Test for 
more than two groups) were used unless otherwise stated.  Normality 
assessments and non-parametric tests were done in GraphPad Prism (LaJolla, 
CA). Linear regressions and correlation coefficients were estimated in GraphPad 
Prism.   
 
Modeling BCR-ABL+ B Acute Lymphoblastic Leukemia in mice allows 
study of the host anti-leukemia immune response 
The adaptive immune system mounts a response to BCR-ABL+ 
leukemia 
To examine whether BCR-ABL+ leukemia elicited an adaptive immune response 
in mice, we adoptively transferred Cdkn2a-/- BCR-ABL+ pre-B cells into healthy, 
immune-competent recipient mice.  This model incorporates two genetic 
alterations common in high-risk human B-ALL: BCR-ABL and loss of the tumor 
suppressor ARF (124).  Further, these cells can be transferred into unconditioned 
host mice where they faithfully form B-ALL (118). The leukemic cells express 
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CD19, B220, IL7R, MHC-II, and low levels of immunoglobulin heavy chain (IgH) 
and therefore closely resemble human progenitor B-ALL (Figure 2-1).  
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Figure 2-1: BCR-ABL+ B-ALL forms in mice.  
A. Phenotype of BCR-ABL+ cells grown in vitro.  Cells were analyzed after 3 weeks in culture, 
and express CD19, B220, GFP, I-Ab, IL7R, and Ig Heavy Chain.  Isotype controls are in grey and 
experimental stains are in black; shown are representative stains.  B. BCR-ABL+ leukemic cell 
phenotype in vivo.  Live lymphocytes are gated for CD19+ B220+, and CD45.1+GFP+ events are 
leukemic cells. 
 
In syngeneic (C57BL/6) hosts, leukemia arose in the bone marrow and the 
splenic red pulp with small numbers of leukemic cells in the lymph nodes (Figure 
2-2).  Of note, the majority of leukemic cells were i.v.+ in the spleen and i.v.- in 
  48 
the lymph nodes, again supporting that the leukemic cells in the spleen were 
associated with the red pulp. 
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Figure 2-2: Representative leukemic tissue and histology 
A. Representative lymph nodes and spleen from a mouse with leukemia.  B. Representative 
histology of a leukemic mouse spleen at 14 days post-transfer.  Leukemic cells are GFP+(Green) 
and are localized in the red pulp (ERTR7+, magenta).  T cells are stained with CD3 in Red. C, D. 
Leukemic mice were injected with anti-CD45.1(PerCP-Cy5.5) i.v. and harvested three minutes 
later.  Flow cytometry was used to analyze the fraction of leukemic cells which were i.v.+ or i.v.- 
in the Spleen or Lymph Nodes.  Two independent repeats were conducted, statistics were 
analyzed by Mann-Whitney U test. 
To determine if the adaptive immune system had any control over BCR-ABL+ B-
ALL progression we compared leukemic cell counts (referred to hereafter as 
leukemic burden) in C57BL/6 and OT-IxRag2-/- mice.  OT-IxRag2-/- mice were 
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used because they have T cells but no leukemia-specific adaptive immunity.  The 
percentage of leukemic (CD45.1+, GFP+) B cells in the bone marrow (BM) was 
significantly higher in OT-IxRag2-/- mice than in C57BL/6 mice (Figure 2-3). 
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Figure 2-3: Leukemic burden varies with presence of adaptive immunity 
GFP+ cells in BM as a percentage of the CD19+B220+ cells in C57BL/6 and OT-IxRag2-/- hosts.  
Twenty days after leukemic cell transfer BM cells were harvested from WT or OT-IxRag2-/- hosts 
and CD19+B220+GFP+ cells were gated as in A.  GFP+ cells in BM as a percentage of the 
CD19+B220+ cells are graphed.  P-value from Mann-Whitney U Test.  Data shown from three 
separate experiments. 
 
Steady-state vs. peptide-CFA immunization of two leukemia-specific 
T cell populations 
BAp:I-Ab-specific T cells in naïve mice. 
We studied the interaction between BCR-ABL+ B-ALL and CD4+ T cells by 
tracking leukemia-specific T cells.  Since BCR-ABL is a somatic mutation, the 
peptide spanning the fusion of BCR to ABL could potentially elicit a T cell 
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response.  Using an ELISpot assay, we found a MHC-II binding peptide in the 
BCR-ABL fusion that elicited a CD4+ T cell response (Figure 2-4), and 
constructed a peptide:I-Ab monomer wherein this peptide (BAp) was covalently 
linked to biotinylated I-Ab (referred to as BAp:I-Ab).   Of note, it is surprising that 
the BAp peptide was peptide #8.  BAp is made up of sequence that is ~85% from 
ABL and only ~15% from BCR.  Our hypothesis was that a peptide such as 
peptide #5 (which is approximately 50:50 derived from BCR vs. ABL) would have 
been the most immunogenic.  However, if major contact residues are the defining 
feature of TCR recognition of cognate peptide: MHC, then previously published 
work would support that peptide #8 should be the best binding peptide, since it 
most closely aligns with high-quality contact residues (125). 
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Figure 2-4: BCR-ABL elicits an immune response in C57BL/6 mice 
A. Immunized mice expressed IFNγ when exposed to BCR-ABL.  Peptides 1-8 on the X-axis are 
13aa peptides that progressively span the BCR-ABL e1a2 fusion (top panel, asterisk represents 
the fusion junction).  Mice were immunized with the full e1a2 20aa peptide.  Two weeks later, 
cells were harvested from SLO and separate wells were pulsed with individual peptides 1 through 
8 and then stained with anti-IFNγ.  B. Five mouse repeats are shown.   
We labeled BAp:I-Ab-specific T cells by tetramerizing BAp:I-Ab monomer with 
Streptavidin-PE or Streptavidin-APC.  Using this reagent, we detected ~8 BAp:I-
Ab-specific CD4+ T cells per mouse (Figure 2-5).  No BAp:I-Ab-specific T cells 
were detected in OT-IIxRag2-/- and SM1xRag2-/- mice, where all T cells are 
specific for an ovalbumin or a flagellin peptide bound to I-Ab, respectively, 
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demonstrating specificity of the BAp:I-Ab tetramer for the BAp:I-Ab-specific T cell 
TCR.  
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Figure 2-5: BAp:I-Ab tetramer detects T cells in C57BL/6 mice 
A. Enumeration of BAp:I-Ab-specific T cells from C57BL/6, OT-IIxRag2-/-, and SM1xRag2-/-.  
Shown are 44 mice from 10 experiments, y-axis is the Log(Y+1) of the BAp:I-Ab-specific T cell 
count.  B. Naïve BAp:I-Ab-specific T cells are Dump-, CD8-, and CD4+.  Dump-CD8+ (top panel) or 
Dump-CD4+ (bottom panel) T cells were gated on and stained with BAp:I-Ab-APC (Y-axis) and 
BAp:I-Ab-PE (X-axis). C. Representative flow plot of T cells from a C57BL/6 mouse BAp:I-Ab 
tetramers labeled with APC and PE, 14 days after immunization with BAp peptide plus adjuvant.   
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The BAp:I-Ab-specific T cells typically expressed low levels of canonical 
activation markers including CD11a and PD1 in naïve mice, however expression 
of CD44 and FR4 were significantly, albeit modestly, increased on BAp:I-Ab-
specific T cells in naïve mice (Figure 2-6).   
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Figure 2-6: BAp:I-Ab tetramer-binding cell phenotype at steady-state 
Phenotype of BAp:I-Ab-specific T cells from naïve mice (black lines) compared to the bulk CD4+ 
population from the same mouse (grey lines).  Shown are results from three independent 
experiments whose events were then concatenated for the histograms.  All comparisons were 
made with Mann-Whitney U test (2 groups). Shown are 10 mice from 3 independent experiments, 
whose events were then concatenated for the histograms.  
Nonetheless, all of these markers were uniformly expressed at high levels 
following BAp peptide + CFA immunization demonstrating that the BAp:I-Ab-
specific T cells responded to cognate peptide immunization (Figure 2-5, Figure 
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2-7). Taken together, these findings show that BAp:I-Ab-specific T cells are 
capable of responding to BAp antigen. 
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Figure 2-7:BAp:I-Ab tetramer-binding cell phenotype upon immunization  
BAp:I-Ab-specific T cells from mice immunized with peptide plus adjuvant 14 days later (black 
lines).  Grey histograms are bulk CD4+ T cells.  Shown are 10 mice from 3 independent 
experiments, whose events were then concatenated for the histograms.  The numbers are 
percentage of cells falling into each given gate.   
 
BAp:I-Ab-specific T cells respond to BCR-ABL+ B-ALL 
 Despite their limited numbers, we hypothesized that BAp:I-Ab-specific T cells 
might still respond to BCR-ABL+ leukemia.  To test this hypothesis, we tracked 
BAp:I-Ab-specific T cells following adoptive transfer of leukemic cells into 
C57BL/6 mice and observed a significant accumulation of BAp:I-Ab specific T 
cells at 14 and 25 days post-transfer of BCR-ABL+ leukemic cells (Figure 2-8).  
CD44 expression on BAp:I-Ab-specific T cells also increased in a stepwise 
fashion at 14 and 25 days post-transfer, suggesting that these cells were 
recognizing antigen in leukemic mice (Figure 2-8).  
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Figure 2-8: BAp:I-Ab-specific T cells experience antigen and respond to BCR-ABL+ 
leukemia in vivo 
A. 2,500 live BCR-ABL+ leukemic cells were transferred into mice.  BAp:I-Ab-specific T cells were 
counted at fourteen days or twenty-five days post-inoculation. Y-axis is the Log (Y+1) of the 
BAp:I-Ab-specific T cell count.  Cumulative results from more than three experiments are shown; 
data is from greater than three independent experiments.  B. Percent CD44-high expression on 
BAp:I-Ab-specific T cells.  The data was collected as in A. 
 
This response was antigen-specific as BAp:I-Ab-specific T cells did not proliferate 
or upregulate CD44 in response to a BCR-ABL negative leukemia.  Thus, BAp:I-
Ab-specific cells proliferate but do not eliminate leukemia.  Additionally, we 
inoculated mice with a previously described BCR-ABL- adoptive transfer B-ALL 
“SP1” and found that BCR-ABL- B-ALL did not induce expansion or upregulation 
of CD44 on BAp:I-Ab-specific T cells (Figure 2-9).  While the experiments using 
SP1 cells yielded very few BAp:I-Ab-specific T cells (which makes phenotypic 
analysis of these cells challenging) the result of having detected few BAp:I-Ab 
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tetramer-binding events in SP1 leukemic mice also supports the conclusion that 
BAp:I-Ab-specific T cells are likely not proliferating in response to BCR-ABL- 
(SP1) leukemia. 
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Figure 2-9: BAp:I-Ab-specific T cells do not proliferate or experience antigen in response to 
BCR-ABL- B-ALL 
A. C57BL/6 mice were adoptively transferred with SP1 leukemia (120).  Fourteen days later, SLO 
were harvested from three independent mice and stained with BAp:I-Ab tetramer.  Samples were 
analyzed by flow cytometry.  Shown is Dump-CD4+CD8-, Tetramer double positive.  In SP1-
leukemic mice, three events were uncovered.  B. CD44 expression was analyzed on BAp:I-Ab-
specific T cells from the mice harvested in A.  30% of the BAp:I-Ab-specific T cells were CD44+ 
and the majority (66%) were CD44-, suggesting these cells had not experienced cognate BAp:I-
Ab.  
 
BCR-ABL+ leukemic cells also expressed a GFP reporter, making GFP a 
leukemia-specific neo-antigen in leukemic C57BL/6 mice.  We used a GFP:I-Ab-
specific tetramer (126) to examine if neo-antigen specific T cells behave similarly 
to BAp:I-Ab-specific T cells in response to leukemia.  While BAp:I-Ab-specific T 
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cells proliferated as much in response to leukemia (53-fold) (Figure 2-10) as they 
did in response to BAp peptide plus adjuvant (47-fold) (Figure 2-11), GFP:I-Ab-
specific T cells proliferated only 17% as much in response to leukemia (66-fold) 
(Figure 2-10) as GFP peptide plus adjuvant (366-fold) (Figure 2-11).  Importantly, 
the ratio of GFP:I-Ab specific T cells to GFP+ leukemic cells was not different than 
the BAp:I-Ab-specific T cell-to-leukemic cell ratio (Figure 2-10).  Thus, the 
proliferation of neo-antigen specific T cells responding to BCR-ABL+ B-ALL is 
inhibited. 
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Figure 2-10:GFP:I-Ab-specific T cells respond to BCR-ABL-IRES-GFP+ leukemia  
A. Fold increase in antigen-specific T cell count between naïve (N) mice and leukemic (L) mice.  
B. Target-to-effector ratio of leukemic mice, either tracking BAp-specific T cells or GFP-specific T 
cells; three independent experiments shown.  All comparisons were made with Mann-Whitney U 
test (2 groups) or Kruskal-Wallace test (>2 groups). 
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Evidence for cross reactivity vs. neo-antigen specificity of leukemia-
specific T cell populations 
BAp vs. GFP:I-Ab-specific T cell responses to CFA + peptide 
immunization 
We next examined whether BAp:I-Ab specific T cells had comparable proliferative 
capacity to other antigen-specific naïve T cells. We found that in response to 
peptide plus adjuvant immunization, BAp:I-Ab-specific T cells proliferated 
modestly (47-fold, Figure 2-11).  BAp:I-Ab-specific T cell proliferation resembled 
that observed with GFP:I-Ab-specific T cells in Foxp3-GFP mice (18-fold), where 
GFP is a self-antigen.  In contrast, immunization with GFP in C57BL/6 mice (in 
which GFP is a foreign antigen) resulted in a 366-fold expansion of GFP:I-Ab 
specific T cells (Figure 2-11).  Thus BAp:I-Ab-specific T cell expansion resembled 
that seen for T cells that recognized low abundance self-antigens (GFP in Foxp3-
GFP mice). 
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Figure 2-11: BAp:I-Ab-specific T cells proliferate similarly to known cross-reactive T cells 
C57BL/6 or Foxp3-GFP mice were immunized with BAp or GFP peptide + CFA.  Secondary 
lymphoid organs were harvested 14 days later and BAp:I-Ab-specific or GFP:I-Ab-specific T cells 
were enumerated.  Y-axis is the Log (Y+1) of the BAp:I-Ab-specific T cell count or the GFP:I-Ab-
specific T cell count.  The number above the line is the fold change from median (indicated by 
black bars).  All fold expansions shown resulted in significantly higher T cell counts than in 
unimmunized mice; >2 independent experiments were conducted for each immunization shown.   
 
Cross-reactivity of BAp:I-Ab-specific T cells with the self 
peptide ABL 
T cell-based cancer immunotherapy is thought to be more effective when T cells 
recognize cancer cell neo-antigens with minimal cross-reactivity for self-antigens 
(127).  Thus, we addressed if BAp:I-Ab-specific T cells recognized neo-antigens 
or cross-reactive self-antigens.  Recent studies have shown that small 
peptide:MHC-II specific T cell repertoires are predictive of cross-reactivity with 
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self-antigen (128).  The BAp peptide (DAEALQRPVASDF) closely resembles the 
endogenous ABL peptide (LEEALQRPVASDF) (85% identical, see underlined 
portion), so we tested if BAp:I-Ab tetramer-binding T cells could recognize the 
overlapping ABL peptide.  When mice were immunized with adjuvant plus ABL 
peptide, BAp:I-Ab tetramer-binding cells proliferated 46-fold, which is similar to 
the proliferation seen after immunization with BAp peptide plus adjuvant (Figure 
2-12).  This evidence suggests that BAp:I-Ab-binding T cells are cross-reactive 
with the self-peptide ABL.  These results may explain the occasional expression 
of CD44 that we saw on BAp:I-Ab-specific T cells in naïve mice (Figure 2-6). 
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Figure 2-12: BAp:I-Ab-specific T cells cross-react with a peptide from ABL 
C57BL/6 mice were immunized with BAp peptide or ABL peptide emulsified in CFA.  14 days 
later, secondary lymphoid organs were harvested as previously described.  Y-axis is the Log 
(Y+1) of BAp:I-Ab tetramer-binding events; data is from three independent experiments.  All 
comparisons were made with Kruskal-Wallace Test (>2 groups). 
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BAp:I-Ab specific T cell numbers in naïve mice are controlled 
by central tolerance 
The precursor frequency of BAp:I-Ab-specific T cells was quite low (Figure 2-5), 
thus we examined whether immune central tolerance may be limiting the number 
of BAp:I-Ab-specific T cells in naïve mice.  Bim-/- mice, which have defective 
thymic negative selection, had significantly (~5 fold) more BAp:I-Ab-specific T 
cells (Figure 2-13) (74, 75, 129).  Thus, ~80% of the BAp:I-Ab-specific T cell 
progenitors were deleted during thymic negative selection.  
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Figure 2-13: Bim-/- mice have more BAp:I-Ab-specific T cells at steady state than C57BL/6 
mice  
BAp:I-Ab-specific T cells were enumerated from Bim-/- mice and compared to C57BL/6.  Y-axis is 
the Log (Y+1) of the BAp:I-Ab-specific T cell count and three independent experiments are shown.  
Significance was calculated with the Mann-Whitney U test. 
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Bim-/- BAp:I-Ab-specific T cells do not have increased tetramer 
Mean Fluorescence Intensity 
We next reasoned that the BAp:I-Ab-specific T cell clones, which were rescued in 
Bim-/- mice, might have high affinity for cognate BAp:I-Ab.  To examine this issue, 
we analyzed the tetramer mean fluorescence intensity of BAp:I-Ab tetramer 
binding cells and normalized this value to that found in the matching bulk CD4+ T 
cell compartment.  Interestingly, we found that the tetramer mean fluorescence 
intensity was significantly higher in the C57BL/6 mice than in the Bim-/- mice 
(Figure 2-14).   
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Figure 2-14: Bim deficiency does not allow BAp:I-Ab-specific T cells to bind tetramer with 
higher affinity or avidity. 
BAp:I-Ab-specific T cells were harvested from C57BL/6 or Bim-/- mice and BAp:I-Ab tetramer mean 
fluorescence intensity (PE channel) was measured.  Shown are 3 independent experiments, p-
value is from Mann-Whitney U Test.  Significance was calculated with the Mann-Whitney U test. 
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Bim-/- BAp-specific T cells do not respond better to 
peptide/CFA immunization 
In addition, when we immunized Bim-/- mice with BAp peptide emulsified in CFA, 
we saw no increase in the number of BAp:I-Ab-specific T cells recovered from 
Bim-/- mice (Figure 2-15).  Thus, Bim-/- mice have an increased number of BAp:I-
Ab-specific T cells, but these cells do not appear to bind cognate BAp:I-Ab with 
higher affinity, nor do these cells accumulate to higher numbers upon 
immunization. 
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Figure 2-15: Bim deficiency does not allow BAp:I-Ab-specific T cells to proliferate more in 
response to peptide/CFA immunization  
C57BL/6 or Bim-/- mice were immunized with BAp peptide emulsified in CFA, and BAp:I-Ab-
specific T cells were harvested from the spleen and lymph nodes 14 days later and these cells 
were enumerated.  Y-axis is the Log (Y+1) of the BAp:I-Ab-specific T cell count.  Shown is data 
from 2 independent experiments, significance was calculated with the Mann-Whitney U test. 
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Bim-/- mice do not allow for more protection after prophylactic 
vaccination 
Bim is also important in contraction of T cells following acute infection (130).  
Since Complete Freund’s Adjuvant leaves an antigen depot and thus likely does 
not truly cause contraction or create immunological memory, we reasoned that 
Bim-/- BAp:I-Ab-specific T cells might respond better to an acute vaccination 
where antigen was formally cleared.  Thus, we infected mice with LCMV-
Armstrong and provided exogenous synthetic BAp peptide at three and five days 
post-infection (Figure 2-16).  We have used this infection strategy as a method to 
boost strong antigen presentation of BAp:I-Ab and robust expansion of the BAp:I-
Ab-specific T cells.  We then re-challenged mice with BCR-ABL+ leukemia greater 
than 40 days later, with the hypothesis Bim-/- mice would be better able to reject 
leukemia upon rechallenge if contraction had not limited the BAp-specific T cells 
to the same degree that it would in Bim-replete mice.  To the contrary, we found 
that Bim-/- hosts actually trended towards succumbing to leukemia faster than 
Bim-replete hosts.  If Bim expression was inducing aggressive central tolerance 
and/or contraction after infection that inhibited BAp:I-Ab-specific T cell function 
the prediction would have been that Bim-/- mice would survive longer with 
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leukemia, since the leukemia-specific T cells were more abundant.  Thus, this 
data provides evidence supporting the conclusion that Bim deficiency does not 
unleash BAp:I-Ab-specific T cells to optimally function-either during central 
tolerance or during contraction following acute infection. 
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Figure 2-16: Bim-/- mice are not better protected from leukemia challenge after LCMV+BAp 
vaccination  
Bim-/- or Bim-replete hosts were vaccinated with Lymphocytic Choriomeningitis Virus (LCMV)-
Armstrong with the addition of 200µg synthetic BAp peptide provided i.v. at both day 3 and day 5 
post infection (see Chapter 4 methods, “Infections and Immunizations”).  Mice were re-challenged 
with 2500 BCR-ABL+ Leukemic cells at greater than 40 days post-infection and survival was 
analyzed.  Statistics were taken from the Log-Rank (Mantel-Cox) test.  Median survivals are 
reported. 
Conclusion 
Recent studies demonstrate that augmenting immune responses can be an 
effective treatment for cancer (107, 131-134).  While the immune system 
recognizes both tumor-associated self-antigens and tumor-specific neo-antigens, 
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cell-based immunotherapy approaches have focused on utilizing neo-antigen 
specific T cells, which should not be subject to immune tolerance.  Many of these 
approaches utilize mutations arising in the malignancy that may not drive cancer 
progression, thus potentially allowing immune escape.  Further, most of these 
treatments have been employed in cancers with many non-synonymous 
mutations.  In this study, we examine the immune response to a cancer with few 
non-synonymous mutations by investigating the adaptive immune response to 
the oncoprotein BCR-ABL.  Our approach was informed by using BAp:I-Ab 
tetramers, to track cross-reactive leukemia-specific T cells, and GFP:I-Ab 
tetramers to track neo-antigen specific T cells.  A major finding from our studies 
is that BCR-ABL+ leukemia induces tolerance to both cross-reactive tumor 
associated self-antigens and tumor-specific neo-antigens.  However, the 
mechanism of tolerance differed depending on whether the tumor-derived 
antigen was a cross-reactive tumor antigen or a neo-antigen.  While leukemia 
induced conversion of BAp:I-Ab-specific T cells into Treg cells, it inhibited 
proliferation of GFP:I-Ab-specific T cells without driving Treg induction.  We 
speculate that cross-reactive antigen-specific Treg cells are one mechanism by 
which leukemias induce tolerance to tumor-specific neo-antigens.    
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The murine host may also allow for immune tolerance to leukemia.  In our model, 
the majority of BAp:I-Ab specific T cells are clonally deleted in the thymus, which 
may result in too few BAp:I-Ab specific T cells to effectively clear leukemia.  For 
example, previous studies have shown that increasing the number of antigen-
specific CD4+ T cells enhanced anti-tumor immunity (106).  Though we could 
recover more BAp:I-Ab-specific T cells in Bim-/- mice, our data do not support that 
the increased number of these cells correlates with increased functionality.  In 
support of this, immunization of Bim-/- mice led to the same number of BAp:I-Ab-
specific T cells as seen in C57BL/6 mice that were immunized in the same way. 
Thus, central tolerance may remove BAp:I-Ab-specific T cells but other 
mechanisms also exist that limit functional immune responses to cancer. 
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Chapter 3 Regulatory T cell dynamics during the immune response to 
leukemia 
Introduction 
2T-helper cells can play both beneficial and detrimental roles in the immune 
response to cancer.  Specifically, while Th1-like cells are thought to benefit the 
host in clearing a cancer pathogen insult, regulatory T cells (Treg) often play a 
detrimental role to the host by inhibiting the host immune response to cancer.  
The Farrar lab has a long-standing interest in Treg development, and as such I 
was lucky to have numerous tools and knowledge sources at my disposal for 
exploring Tregs in response to leukemia.  Therefore, I devoted one chapter of my 
                                            
2 A portion of the Chapter 3 data and text is previously published. 
 Manlove, L.S., Berquam-Vrieze, K.E., Pauken, K.E., Williams, R.T., Jenkins, 
M.K.m Farrar, M.A. 2015. Adaptive Immunity to Leukemia Is Inhibited by Cross-
Reactive Induced Regulatory T cells. Journal of Immunology, September 16, 
2015. 
 
  69 
thesis specifically to highlighting a number of findings regarding Tregs and 
leukemia. 
Treg Development in the thymus and periphery 
While many thymocytes develop with under selective “positive” and “negative” 
pressures, some Tregs probably develop through an alternative pathway termed 
“agonist selection”.  Agonist-selected T cells are allowed to survive thymic 
development despite being engendered with a TCR that has high affinity for 
cognate self peptide:MHC (73).  A portion of the peripheral Treg pool is thought 
to develop through the agonist-selected pathway, thus residing in the periphery 
with a high affinity for cognate self-peptide: MHC-II.  A major feature of this 
developmental track is a dependence of these “thymic-derived” Tregs on 
Interleukin-2 (IL2), which has been well studied by our lab and others (135-138).   
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3STAT5 Activation Drives Thymic Treg Lineage Commitment 
CD4+CD25+FOXP3+ Tregs that develop in the thymus  (also known as ‘natural 
Tregs’) constitute 2-4% of CD4 single positive (CD4SP) thymocytes, yet this 
relatively small population plays a critical role in maintaining peripheral tolerance 
and preventing autoimmunity.  The TCR repertoire of these natural Tregs 
overlaps with that of non-regulatory T cell populations but is skewed to favor 
TCRs that interact with higher affinity to self-antigens in the thymus (140-145).  
The molecular mechanisms that drive Treg development have been tied to three 
primary signaling modules.  First, TCR signaling plays a key role as TCRs with 
higher affinity TCRs for self-antigen are preferentially selected into the Treg 
                                            
 
3 A portion of this introduction is previously published as a review article.  The 
portions included in this introduction were co-authored, and full 
acknowledgement is given to Shawn Mahmud and Michael Farrar for their 
extensive contributions.  
Mahmud, S. A., L. S. Manlove, and M. A. Farrar. 2013. Interleukin-2 and STAT5 
in regulatory T cell development and function. Jak-Stat 2: e23154. 
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lineage (142, 146).  Second, the costimulatory receptor CD28 also plays an 
important role as Cd28-/- and B71/2-/- mice both show clear defects in Treg 
development (147-150).  Third, signals emanating from the interleukin-2 receptor 
are also required for Treg differentiation in the thymus (138, 151).  These 
observations culminated in the development of a two-step model of thymic Treg 
development, in which a TCR- and CD28-dependent, but cytokine-independent 
first step generates an IL2-responsive intermediate “Treg progenitor” that lacks 
FOXP3 expression. Subsequently, a TCR-independent, IL2/STAT5-dependent 
second step results in the rapid conversion of Treg progenitors into mature 
FOXP3+ Tregs (137, 152).  Additionally, recent work suggests that an 
intermediate step between TCR signaling and CD25 expression may be 
costimulation via Tumor Necrosis Factor Receptor Super Family (TNFRSF) 
(153). 
 
Upon interacting with medullary APCs presenting self-peptide:MHC II complexes, 
strong TCR signals in a fraction of CD4SP thymocytes cause them to 
differentiate into Treg progenitors, marked by elevated expression of the high-
affinity IL2Rα chain (CD25), the IL2Rβ chain (CD122), and the costimulatory TNF 
receptor superfamily member, glucocorticoid-induced TNF-related protein (GITR) 
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(137, 152).  The emergence of this CD4+CD25+CD122hiGITRhiFOXP3- Treg 
progenitor population requires canonical activation of the NF-κB pathway 
downstream of TCR and CD28 ligation. Paired activation of LCK from these 
receptors(149) signals through the canonical NF-κB pathway to ultimately 
promote nuclear translocation of c-REL and REL-A(149, 154-157).  The 
requirement for NF-κB activation in Treg differentiation is demonstrated by the 
absence of thymic Tregs—and importantly, Treg progenitors—in animals 
deficient in Cd28, Prkcq, Carma1, Bcl10, and Rel (148, 149, 158-160). Further 
studies revealed that c-REL binds the conserved non-coding sequence 3 (CNS3) 
located in the Foxp3 promoter to promote epigenetic modification of Foxp3 
rendering it permissive for subsequent transcription initiation (161).  
 
The conversion of FOXP3- Treg progenitors into mature FOXP3+ Tregs in the 
thymus occurs via a TCR-independent but IL2/STAT5-dependent process(137, 
152). Ligand binding by the high affinity IL2R complex leads to phosphorylation 
of three key tyrosine residues located in the cytoplasmic domain of IL2Rβ by the 
kinases JAK1 and JAK3.  Phosphorylation of Tyr-338 recruits the SH2-containing 
adaptor molecule, SHC, facilitating activation of the RAS/MAPK/ERK and 
PI3K/AKT pathways via GRB2 and GAB2, respectively. Phosphorylation of IL2Rβ 
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at Tyr-510 (and to a lesser degree Tyr-392) is critical for recruiting and activating 
STAT5 (162). The importance of IL2R signaling in thymic Treg differentiation is 
clearly demonstrated by the fact that the lethal autoimmunity in mice lacking Il2rb 
is due to a failure to generate thymic Tregs, and this phenotype is completely 
restored by adoptive transfer of small numbers of wild type Tregs(163). 
Moreover, retroviral transduction of Il2rb-/- bone marrow with wild type Il2rb, or a 
mutant construct capable of activating only STAT5 via Tyr-510, restored thymic 
Treg generation in bone marrow chimeric mice. In contrast, restoration of Treg 
development did not occur when mutant constructs capable of activating 
RAS/PI3K, but not STAT5, were transduced into Il2rb-/- bone marrow cells and 
engrafted into recipient mice(138).  Likewise, crossing Il2rb-/- mice to transgenic 
mice expressing a constitutively active form of STAT5b (Stat5b-CA mice) 
restored Treg development in the thymus(138). Additional support for the role of 
STAT5 in Treg development came from two studies that demonstrated that 
conditional deletion of STAT5 in DP thymocytes (i.e., Cd4-Cre x Stat5a/bFL/FL 
mice) had minimal effects on CD4SP thymocytes with the exception of 
CD4+FOXP3+ thymic Tregs (138, 164). Together, these findings indicate that 
STAT5 activation downstream of IL2R is required for thymic Treg development. 
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Two groups have demonstrated that CD4+CD25+FOXP3- thymocytes are direct 
precursors of FOXP3+ Tregs, which require only an additional IL2R/STAT5-
dependent signal to express FOXP3.  First, Hsieh and colleagues showed that 
adoptive transfer of CD4+CD25+FOXP3-, but not CD4+CD25-FOXP3- thymocytes, 
into the thymii of wild type hosts resulted in the development of CD4+FOXP3+ 
Tregs.  Similar results were observed upon adoptive transfer into MHCII-deficient 
mice demonstrating that the conversion process did not require additional signals 
via the TCR(152).  In addition, stimulation of sorted Treg progenitors with IL2 in 
vitro led to induction of Foxp3 mRNA within a few hours followed by the 
development of CD4+FOXP3+ Tregs 24 hours later. These findings were 
subsequently confirmed by Burchill and colleagues(137).  
  
IL2, STAT5 and induced Tregs 
An important feature of peripheral tolerance is the conversion of naïve CD4+ T 
cells into induced regulatory T cells (iTregs) in peripheral lymphoid organs.  
iTregs have important roles in protecting against chronic inflammatory conditions, 
and likely play a key role in regulating immune responses to commensal 
microorganisms(165, 166).  The differentiation of iTregs, like nTregs in the 
thymus, requires both TCR and IL2-dependent signals.  However, unlike nTregs, 
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iTregs require Transforming Growth Factor-B (TGFβ) for their differentiation 
(167).  Moreover, while the CARMA1/NFkB pathway is required for the 
development of nTregs it actually antagonizes iTreg differentiation(168).  Finally, 
the stability of iTregs is lower than that of nTregs (169, 170), a feature that 
correlates with the greater degree of DNA methylation of the CNS2 region of the 
Foxp3 gene in iTregs versus nTregs (171).  Thus, iTregs differ in several ways 
from nTregs. 
 
A role for IL2 in iTreg development was established many years ago in studies 
documenting the role of both TGFβ and IL2 in iTreg differentiation (172, 173).  
Likewise, STAT5 also plays an important role in iTreg differentiation in vitro 
(164).  More recent studies have demonstrated that IL2 and STAT5 also play 
critical roles in maintaining stability of the iTreg lineage (169).  Specifically, these 
studies demonstrated that transfer of iTregs into lymphopenic hosts resulted in 
loss of FOXP3 expression in the transferred iTregs.  This result could be blocked 
by co-administration of agonist IL2: anti-IL2 complexes indicating that IL2 was 
required to maintain FOXP3 expression in iTregs in vivo.  These studies further 
documented that the loss of Foxp3 expression correlated with re-methylation of 
the CNS2 region (also referred to as regulatory T cell Specific Demethylated 
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Region or TSDR) of the Foxp3 gene, and that IL2 stimulation prevented this re-
methylation process.  The mechanism by which this occurs remains unclear.  
However, STAT5 binding sites are found in the CNS2 region, which may be 
important for maintaining Foxp3 expression.  It is also possible that STAT5 
directly initiates demethylation of this region as naïve CD4+FOXP3+ T cells are 
converted into CD4+FOXP3+ iTregs.  Arguing against this possibility is evidence 
that STAT5 binds poorly to its cognate DNA binding site when it is methylated 
(174, 175).  However, only one of the three potential STAT5 binding sites found 
in the CNS2 region contains a CpG motif that could be methylated (138).  Thus, 
whether IL2 and STAT5 promote demethylation of CNS2 requires additional 
study. 
 
As mentioned above with regard to thymic Treg development, STAT5 interacts 
with a number of potential binding partners.  The role of these binding partners in 
iTreg development remains to be defined.  Interestingly, recent work from the 
O’Shea lab has shown that micro RNAs activated by TGFB and Retinoic Acid 
Receptor (RAR) suppress the expression of one of these binding partners, the 
co-repressor NCOR2 (176).  Specifically, this study demonstrated that 
conversion of iTregs into TFH is limited when mir10a is expressed at high levels, 
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such as is the case following TGFβ and RAR signaling in the periphery.  It 
appears that mir10a may have a role in fixing the iTreg cell lineage by 
suppressing conversion of iTregs into either Th17 or TFH cells.  Additional studies 
are needed to more precisely define the role of NCOR2 and other STAT5 
interacting partners on the development and maintenance of regulatory T cells. 
 
What cells give rise to induced Tregs? 
An area of current interest is understanding if all naïve CD4+ T cells have an 
equal chance to become induced Tregs (i.e., is iTreg induction strictly due to 
extrinsic factors, or are some CD4+ T cells intrinsically more capable of becoming 
iTregs?).  Reviews have suggested that the molecular mechanisms are in place 
for Th17 and Treg cells to trans-differentiate (177), and it is well-established that 
the protein Foxp3 binds to a plethora of other transcription factors which may 
prepare chromatin for plasticity into the Th17 (or other) lineages (178, 179).  
However, our data may be the first supporting that a subset of the naïve CD4+ T 
cell population is poised to differentiate into iTreg cells (63).  Additionally, the 
Mueller lab at the University of Minnesota has recently uncovered evidence 
supporting the conclusion that “anergic” CD4+ T cells in the periphery are poised 
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to differentiate into Tregs.  Anergic (sometimes called “exhausted) T cells may be 
phenotypically quite similar to naïve cells, since anergic T cells may 
downregulate canonical markers of antigen experience like CD44 (180).  Thus, it 
is possible that no naïve CD4+ T cell is poised to differentiate into the Treg 
lineage, and instead these cells are all “anergic”. 
Studying Treg functionality in mice 
Studying Treg functionality is a delicate business because ablation of Tregs is 
rapidly lethal (88, 89).  Various depletion strategies have been used in the 
literature, including treatment with cyclophosphamide (181), anti-CD25 (182, 
183), and anti-FR4 (184) to deplete Tregs.  Experimentally, a commonly-used 
model now is the Foxp3DTR/DTR mouse, which has the diphtheria toxin receptor 
knocked in to the Foxp3 locus (115).  These mice can then be treated with 
exceedingly low doses of Diphtheria Toxin (DT) leading to selective, transient 
ablation of the Foxp3+ Treg cells.  
The role of Tregs in cancer is variable.  Many findings in human cancers show an 
infiltration of Tregs into the tumor stroma.  However, these studies are correlative 
with disease outcome and not causative (185-188).  Further, clinical Treg 
depletion has been used for treating cancer, but these therapies are non-specific 
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and it is not clear that the cancer therapy is caused by Treg depletion as 
opposed to some other effect of the treatment.  However, what is clear from 
mouse models using the Foxp3DTR/DTR platform is that Tregs have different 
functionality in different models.  For example, depletion of Tregs using 
Foxp3DTR/DTR was sufficient to prolong survival of mice with Renca cell kidney 
cancer (189).  However, in a mouse model of breast cancer, Treg depletion with 
Foxp3DTR/DTR mice increased survival minimally on its own (where it also 
decreased metastasis formation), but synergized with ionizing radiation to 
prolong survival even further (64).  Taken together, these results all suggest that 
Foxp3DTR/DTR-mediated Treg depletion likely will have a positive impact on 
outcome in our studies, but it is unclear how this will synergize with other 
therapies. 
Tregs clearly have complex roles in regulating immune homeostasis.  The 
purpose of this chapter is to address how Tregs fit into the puzzle of anti-
leukemia immunity in one mouse model of BCR-ABL+ B-ALL. 
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 Leukemia-responding Tregs in steady state, immunization, and 
response to leukemia 
T cells specific for cross-reactive leukemia antigens are 
converted into pTreg cells by leukemia. 
Our studies provide evidence that BAp:I-Ab-specific T cells respond to BCR-ABL+ 
B-ALL despite cross-reactivity with self-antigen.  However, leukemia still 
progresses in C57BL/6 mice, which suggests that mechanisms of tolerance 
inhibit the immune responses by cross-reactive T cells.  Indeed, BAp:I-Ab-specific 
T cells positively correlated with leukemic burden in naïve mice inoculated with 
leukemia (Figure 3-1), suggesting that the BAp:I-Ab-specific T cells might prevent 
immune responses to B-ALL.   
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Figure 3-1: BAp:I-Ab-specific T cells positively correlate with leukemic burden  
Log (Y+1) of the BAp:I-Ab-specific T cell counts (Y-axis) correlates with leukemic burden 
(depicted as the percent of bone marrow B cells, which are GFP+) on the X-Axis.  More than 
three experiments are shown, Spearman correlation is shown. 
A possible explanation was that BAp:I-Ab-specific T cells were regulatory T cells 
(Treg cells).  Both naïve Foxp3-GFP mice and Foxp3-GFP mice immunized with 
BAp plus adjuvant typically had no or few BAp:I-Ab specific Treg cells whereas 
the majority of BAp:I-Ab specific T cells in leukemic mice were FOXP3-GFP+ 
(Figure 3-2).  This contrast supports the conclusion that B-ALL converts BAp:I-
Ab-specific T cells into pTreg cells, and provides a mechanism for host tolerance 
of leukemia. 
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Figure 3-2: Leukemia selectively induces BAp:I-Ab-specific Tregs  
Mice were unimmunized, immunized with CFA+BAp, or injected with 2500 BCR-ABL+ cells; 
percentage of BAp:I-Ab-specific Tregs were analyzed 14 days post-inoculation.  >2 independent 
experiments for each group are shown, Kruskal-Wallace test performed (>2 groups). 
 
Peripheral cross-reactivity enhances conversion to Treg 
lineage in response to leukemia 
We next determined if leukemia-specific Treg polarization was related to the 
cross-reactivity of BAp:I-Ab-specific T cells with self-antigen.  To address this 
question, we examined both neo-antigen specific T cells and cross-reactive T 
cells responding to leukemia.  The leukemic cells used in these experiments 
express both GFP and BCR-ABL, thus GFP was a leukemia-specific neo-antigen 
in C57BL/6 mice and BCR-ABL was a cross-reactive antigen in C57BL/6 mice.  
We enumerated GFP:I-Ab-specific Treg cells responding to leukemia in Foxp3-
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RFP mice (where GFP is a non-self antigen) and Foxp3-GFP mice (where GFP 
is a self-antigen).  Most GFP:I-Ab-specific T cells did not polarize into FOX3-RFP+ 
Treg cells in response to leukemia (1.5% +/- 1.7%).  In contrast, significantly 
more GFP:I-Ab-specific T cells were Treg cells in leukemic FOXP3-GFP mice 
(8.3% +/- 31.2%, p<0.005; Figure 3-3).   
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Figure 3-3: Cross-reactivity with self-antigen potentiates leukemia-specific Treg 
conversion 
Percent of BAp:I-Ab-specific T cells that are FOXP3+ Treg cells in Foxp3-dsRed or Foxp3-GFP 
mice. 2,500 BCR-ABL+ B-ALL cells were transferred into Foxp3-RFP or Foxp3-GFP mice and 
BAp:I-Ab-specific T cells were enumerated 14 days later.  Y-axis is percentage of BAp:I-Ab-
specific T cells that are FOXP3+ Treg cells in their respective hosts.  >2 independent experiments 
are shown for each group, Mann-Whitney U test performed (2 groups). 
 
 
Importantly, 75% of naïve Foxp3-GFP mice contained no GFP:I-Ab-specific Treg 
cells (Figure 3-4), suggesting that GFP:I-Ab-specific Treg cells seen in leukemic 
Foxp3-GFP mice were induced Treg cells.   
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Figure 3-4: 75% of naïve GFP:I-Ab-specific T cells are not Tregs at steady-state  
SLO were harvested from naïve Foxp3-GFP mice, and GFP:I-Ab-specific T cells were 
enumerated; FOXP3-GFP expression was evaluated on these cells.  The Y-axis shows the 
log(Y+1) of GFP:I-Ab-specific T cell count from these mice. 
 
Thus, peripheral CD4+ T cells that cross-react with self have increased capacity 
to become pTreg cells in response to leukemia.   
 
Histologically, Treg cells were localized in the splenic red pulp, adjacent to red 
pulp macrophages and leukemic cells (Figure 3-5).   
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Figure 3-5: Localization of leukemic cells, Tregs, and red-pulp macrophages in leukemic 
mice 
A. Representative histology of spleen from a C57BL/6 mouse 14 days after leukemic cell transfer.  
Blue is F4/80, Red is CD11C, Magenta is CD31, and Green is GFP+(leukemic cells).  b. 
Representative histology from spleen as in A, showing FOXP3+ Treg cells in the splenic red pulp.  
Red is CD3, White is FOXP3, Green is GFP+ (leukemic cells).    
 
Red pulp macrophages have been shown to induce Treg cells in vitro (190).  
Thus, Tregs responding to leukemia antigens are preferentially cross-reactive, 
and localized in an immune-suppressive microenvironment near the leukemic 
cells. 
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The role of Tregs in the anti-leukemia immune response 
Tregs allow leukemia progression in C57BL/6 mice. 
To determine if Treg cells inhibited the immune response to BCR-ABL+ leukemia, 
we selectively ablated Treg cells using Foxp3DTR/DTR mice (115).  Transient 
depletion of Treg cells led to a 98% decrease in leukemic burden in the BM at 
fourteen days post-inoculation with leukemia (Figure 3-6).  Depletion of Tregs 
following leukemia inoculation also led to an increased survival of mice as 
compared to untreated C57BL/6 mice (Figure 3-7).  
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Figure 3-6: Diphtheria Toxin treatment strategy and survival in leukemic Foxp3DTR/DTR mice 
A.  Foxp3DTR/DTR or C57BL/6 mice were inoculated with 2500 leukemic cells and then treated with 
Diphtheria Toxin (DT) at 0.25µg/kg DT daily, and compared to C57BL/6 mice treated with DT.  B. 
Foxp3DTR/DTR mice were treated as in C and survival was analyzed.  P-values from Log-rank test; 
three independent experiments shown. 
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In parallel BAp:I-Ab-specific T cells proliferated ~30-fold more in DT-treated 
Foxp3DTR/DTR mice than in DT-treated C57BL/6 mice (Figure 3-7).   
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Figure 3-7: Treg depletion allows increased BAp:I-Ab-specific T cell numbers in correlation 
with decreased leukemic burden  
A. Log(Y+1) of the BAp:I-Ab-specific T cell count in Foxp3DTR/DTR mice and C57BL/6 mice 
inoculated with leukemia and treated with DT as in A.  Three independent experiments are 
shown.  B. Mice were harvested at 14 days post-inoculation and leukemic cells were enumerated 
from the spleen and lymph nodes.   
 
 
Treg Depletion Timing and Leukemia Survival 
We noticed that some Foxp3DTR mice survived longer when given leukemia and 
treated with DT compared to only being treated with DT (and not having 
leukemia) (Figure 3-8).  This hinted that the leukemic cells had an 
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immunosuppressive capacity in-and-of themselves.  Interestingly, there was no 
statistically significant difference in overall survival as analyzed by the Log-Rank 
(Mantel-Cox) test.  However, the hazard ratio between the two groups was 0.46, 
and the shapes of the curves suggest that at least some leukemic mice outlive 
the DT-treated non-leukemic mice.  As well, the mean survival for leukemic mice 
is slightly longer than for non-leukemic mice.  Further, this analysis may be 
hampered because the endpoints are implicitly different between the 
DT+leukemia mice and the DT-leukemia mice.  Most of the DT+leukemia mice 
were euthanized bilateral hind-limb paralysis, as per IACUC protocol.  
Meanwhile, the DT-leukemia mice never developed hind limb paralysis, and thus 
never reached the same endpoint.  Instead, the DT-leukemia endpoint was when 
mice would not voluntarily eat.  This timepoint coincided with many overt signs of 
IPEX.  Thus, we conclude that the leukemic cells may be able to “rescue” the 
immunosuppression lost in some leukemic DT-treated Foxp3DTR/DTR mice, but 
that a survival analysis may not be the best depiction of this.  
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Figure 3-8: Survival of Treg-depleted non-leukemic mice compared to Treg-depleted 
leukemic mice hints that leukemia protects Treg-depleted mice from IPEX-like pathologies 
Foxp3DTR/DTR mice were either adoptively transferred with 2500 BCR-ABL+ leukemic cells and 
then treated with 0.2µg Diphtheria Toxin (DT) i.p. every-other-day for the remainder of their 
survival (DT + leukemia, black line) or not transferred with leukemia, but treated with DT as above 
(DT – leukemia, blue line).  Survival was compared by the Log-rank (Mantel-Cox) test, which 
resulted in an insignificant difference in survival.  Also reported is the hazard ratio (0.46), the 95% 
confidence interval of the hazard ratio, and the median survival. 
 
We then wanted to explore if perhaps some of the DT-treated leukemic 
Foxp3DTR/DTR mice were dying from IPEX and not from leukemia.  To test this, we 
treated leukemic Foxp3DTR/DTR mice with an ‘induction’ dose of DT (0.2ug every-
other-day for one week) followed by weekly DT treatment.  This dose should 
cause far less Treg depletion than every-other-day DT treatment, and therefore 
should limit IPEX-related pathologies.  Contrary to our hypothesis, we found that 
the induction + 1x/week DT treated mice had decreased overall survival 
compared to treating with DT every-other-day.  Thus, this data suggests that 
constant “tamping-down” of the Treg population is required to allow survival in 
leukemic mice-even though this dosage may flirt with inducing IPEX.  This data 
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could be supporting a model where some sort of immune-suppressive cell is 
required to prevent IPEX in mice; this cell could be a leukemic cell, a Treg, or a 
combination of the two.  Depleting Tregs without providing leukemic cells induces 
IPEX-like symptoms (Figure 3-8).  Additionally, our data shows that depleting 
Tregs to a high degree for a long time (DT every-other-day) allows mice to 
survive long from both leukemia and IPEX, while depleting Tregs to a lesser 
degree (induction + 1x/week) allows mice to survive for a significantly shorter 
amount of time (these mice uniformly developed bilateral hind-limb paralysis, 
suggesting that they had developed leukemia).  Thus, equilibrium may occur 
between Tregs and leukemic cells that allows for sufficient immune suppression 
to prevent IPEX, but sufficient immune activation to limit leukemia. 
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Figure 3-9: High-level Treg depletion over the course of leukemia progression is required 
for increased survival by Treg depletion 
Foxp3DTR/DTR or C57BL/6 mice were adoptively transferred with 2500 BCR-ABL+ leukemic cells 
and then Foxp3DTR/DTR  were treated with 0.25µg DT every-other-day for 1 week, followed by 
0.25µg DT 1x-per-week after that (DT Induction + 1x/week, blue line), Foxp3DTR/DTR were treated 
with 0.2µg DT every-other-day for the duration of survival (DT Every-other-day, green line) or 
C57BL/6 mice were untreated and survival was analyzed (Historical C57BL/6, black line).  
Survival was compared by Log-Rank (Mantel-Cox) test.  Median survival is also reported. 
 
Another issue was when, during the course of leukemogenesis, Tregs were 
eliciting their immune suppressive function.  While we showed that Treg 
depletion for the entire span of leukemia (Figure 3-5) was critical for survival of 
leukemic mice, this analysis did not clarify if Tregs were important for leukemia 
survival at the onset of leukemia transfer, or at later stages of leukemia 
progression.  To address this question, Foxp3DTR/DTR mice were inoculated with 
leukemic cells and Tregs were depleted starting 14 days after leukemic cell 
transfer.  At this timepoint, the leukemia is well established throughout the body 
(Figure 2-2).  “Late” Treg depletion (starting at 14 days-post-inoculation) resulted 
in increased survival compared to historical C57BL/6 leukemic mice, but 
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decreased survival as compared to DT treatment every-other-day (Figure 3-10).  
Since late Treg depletion resulted in an intermediate increase in survival of 
leukemic mice, this data supports a role for Tregs both early in leukemia onset 
and late during the maintenance/progression of leukemia. 
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Figure 3-10: Treg depletion during advanced-stage leukemia has a partial benefit to the 
host 
Foxp3DTR/DTR or C57BL/6 mice were adoptively transferred with 2500 BCR-ABL+ leukemic cells 
and then Foxp3DTR/DTR were treated with 0.2µg DT every-other-day for the duration of survival (DT 
Every-other-day, blue line), Foxp3DTR/DTR were treated with 0.2µg DT every-other-day for the 
duration of survival starting at 14 days post-leukemia inoculation (14dpi DT Every-other-day, 
orange line) or C57BL/6 mice were untreated and survival was analyzed (Historical C57BL/6, 
black line).  Survival was compared by Log-Rank (Mantel-Cox) test, each group contained at 
least two independent experiments comprising >8 mice.  Median survival is also reported. 
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Transgenic constitutively active STAT5 mice have similar 
leukemic burden to C57BL/6 hosts 
Previous work has shown that certain mouse models such as Statb5CA 
transgenic mice, have increased numbers of Tregs. The STAT5bCA mouse has 
a number of phenotypes in immune cells, including a notable increase in the 
number of Tregs (137).  Since Treg depletion allowed increased survival of 
leukemic mice, our hypothesis was that STAT5bCA mice, with their increased 
number of Tregs, would have a decreased survival when given leukemic cells.  
Indeed, leukemic STAT5bCA mice survived for significantly less time than 
leukemic C57BL/6 mice in the matched experiment, though the survival of 
STAT5bCA mice closely overlays that of historical C57BL/6 leukemia survival 
(Figure 3-11).  Nonetheless, thus, these data suggest that STAT5bCA host mice 
(which have an increased number of Tregs) survive for less time than C57BL/6 
host mice (which should have a ‘normal’ number of Tregs), which supports our 
conclusions that Tregs allow for more aggressive leukemia and thus decreased 
survival from leukemia. 
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Figure 3-11: Leukemic STATb5CA mice have less survival than leukemic C57BL/6 mice  
STATb5CA (blue line) or littermate-control C57BL/6 (orange line) or historical C57BL/6 mice 
(black line) were adoptively transferred with 2500 BCR-ABL+ leukemic cells.  Survival was 
analyzed by Log-Rank (Mantel-Cox) test.  Also shown is median survival.   
 
Tregs inhibit priming and Th1-like skewing of BAp:I-Ab-specific 
T cells 
We next sought mechanistic insight into how the presence of Tregs inhibited the 
leukemia-specific immune response.  We found that the percent of BAp:I-Ab-
specific T cells that were CD44hi was significantly higher in DT-treated 
Foxp3DTR/DTR mice, suggesting that Tregs inhibit priming of BAp:I-Ab-specific T 
cells (Figure 3-12).   We reasoned that Ly6C+ Th1-like cells might also be 
important in controlling leukemia progression (191-193).  Indeed, the fraction of 
CD44+ and Ly6C+ BAp:I-Ab-specific T cells was increased in DT-treated 
Foxp3DTR/DTR mice, suggesting that Tregs inhibit BAp:I-Ab-specific T cell priming 
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and effector differentiation during the immune response to leukemia (Figure 
3-12). 
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Figure 3-12: Treg depletion allows increased antigen experience and Th1-like phenotype in 
BAp:I-Ab specific T cells from leukemic mice 
A.  Experiments were conducted as in Figure 3-6 A; shown is the percent CD44hi BAp:I-Ab-
specific T cells. B. Experiments were conducted as in Figure 3-6 A; shown is the percent Ly6Chi 
BAp:I-Ab-specific T cells. All comparisons were made with Mann-Whitney U test (2 groups). 
 
 
Treg conversion in response to leukemia is dependent on 
TGFβ 
Tregs were clearly important for leukemia progression (Figure 3-6).  However the 
mechanism that drives BAp:I-Ab-specific T cells into the Treg lineage in mice with 
leukemia remains unclear.  One possible explanation is that the leukemic cells 
might produces cytokines that drive Treg conversion.  To address this point, we 
analyzed cytokine production by leukemic cells and by BAp:I-Ab-specific T cells 
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responding to leukemia.  When responding to leukemia, both leukemic cells and 
BAp:I-Ab-specific T cells produced the immune-suppressive cytokines IL10 and 
TGFβ1 (Figure 3-13).   
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Figure 3-13: TGFβ1 and IL10 are produced during leukemia by leukemic cells and BAp:I-
Ab-specific T cells 
A, B. BAp:I-Ab-specific T cells were gated on BAp:I-Ab Tetramer (APC)+, CD44+ and were stained 
for cytokines.  Shown is the median fluorescence intensity of IL10 (A) and TGFβ1 (B).  Three 
independent experiments are shown, comparisons were made with Wilcoxan Matched-Pairs test 
(2 paired groups). C, D. Shown is the overlay of IL10 (C) and TGFβ1 (D) expression on BAp:I-Ab 
Tetramer-, CD44- CD4+ T cells (Blue), BAp:I-Ab Tetramer+, CD44+ CD4+ T cells (Red), and 
Leukemic cells (Black).  Shown are 10 mice from three independent experiments, whose results 
were concatenated.  E, F. Leukemic cells were gated as CD45.1+, GFP+ and were stained for 
cytokines.  Shown is the median fluorescence intensity of IL10 (E) and TGFβ1 (F).  Three 
independent experiments are shown, comparisons were made with Wilcoxan Matched-Pairs test 
(2 paired groups).  
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Since TGFβ1 is important for conversion of naïve CD4+ T cells into peripheral 
Treg cells (139, 167, 194), we reasoned that TGFβ1 might drive BAp:I-Ab-specific 
Treg conversion in response to leukemia.  When leukemic mice were treated with 
anti-TGFβ antibody or isotype control, anti-TGFβ treatment led to significantly 
less BAp:I-Ab-specific Tregs, and significantly more proliferation of BAp:I-Ab-
specific T cells than isotype treatment or historical analyses of leukemic mice at 
the same timepoint (Figure 2-8,Figure 3-14).  These results suggested that 
TGFβ1 was critical for efficient induction of leukemia-specific Tregs in this model.   
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Figure 3-14: TGFβ1 and leukemic cell MHC-II potentiate Treg induction and limit BAp:I-Ab-
specific T cell expansion in leukemic mice  
A. Mice were inoculated with MHC-II replete leukemia or MHC-II-/- leukemia as labeled, or treated 
with Isotype or anti-TGFβ antibody.  BAp:I-Ab-specific Tregs were gated as previously described 
and the percent Tregs was analyzed.  Results are from three independent experiments, Kruskal-
Wallace and Dunns’ test used to establish significance.  B. Mice were treated as in A, and BAp:I-
Ab-specific T cell count was analyzed as previously described.  Results are from three 
independent experiments, Kruskal-Wallace and Dunns’ test used to establish significance.  C. 
BAp:I-Ab-specific T cells from mice inoculated with MHC-II-/- leukemia or MHC-II replete leukemia 
and harvested 14 days later were analyzed for Ly6C expression.  Shown are three independent 
experiments, significance was established with Mann-Whitney U test.  D.  BAp:I-Ab-specific T 
cells from mice inoculated with leukemia and treated with anti-TGFβ or isotype control were 
analyzed for Ly6C expression 14 days later.  Shown are three independent experiments, 
significance was established with Mann-Whitney U test.   
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Treg induction is dependent on MHC-II presentation by 
leukemic cells 
Leukemic cells and Tregs were also in relatively close contact in the splenic red 
pulp (Figure 3-5).  Thus, we reasoned that the leukemic cells might present 
antigen in the context of MHC-II, and initiate Treg induction by simultaneously 
providing TGFβ1.  To test this hypothesis, we generated MHC-II-/- leukemic cells 
and inoculated Foxp3-GFP mice with them.  When we analyzed BAp:I-Ab-specific 
Treg induction 14 days later, we found that significantly fewer BAp:I-Ab-specific T 
cells were Tregs in response to MHC-II-/- leukemia than in response MHC-II 
replete leukemia (either from historical experiments or during experiments done 
at the same time with isotype treatment Figure 3-2, Figure 3-14).  In parallel, 
MHC-II-/- leukemia or anti-TGFβ treatment led to significant increases in Ly6C 
expression on BAp:I-Ab-specific T cells, suggesting that these cells might be 
converted into a Th1-like lineage instead of the Treg lineage (Figure 3-14).  
Additionally, MHC-II-/- leukemia correlated with significantly more proliferation of 
BAp:I-Ab-specific T cells in leukemic mice, again suggesting that the decreased 
BAp:I-Ab-specific Treg conversion might allow for increased proliferation of the 
BAp:I-Ab-specific T cells (Figure 3-14).  Consistent with these findings, we 
observed a significant increase in survival of mice inoculated with MHCII-/- 
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leukemia compared to MHCII-replete leukemia (Figure 3-15).  Together, these 
findings support a mechanism of host protection from leukemia where antigen 
presentation on MHC-II by the leukemic cells induces immune suppression (and 
thus leukemia progresses in the host) while antigen presentation on MHC-II by 
myeloid cells induces immune system activation (and thus leukemia regresses in 
the host).  
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Figure 3-15: MHC-II expression on leukemic cells modulates survival of leukemic mice.  
 Mice inoculated with MHC-II-/- leukemia or MHC-II replete leukemia were aged until leukemia-
induced morbidity and survival to morbidity was analyzed. P-values from Log-rank (Mantel-Cox) 
test; three independent experiments shown.   
Thus, antigen presentation by the leukemic cells enhances induction of BAp:I-Ab-specific T cells 
into the Treg lineage, inhibits proliferation of Ly6C+ BAp:I-Ab-specific T cells and reduces survival 
of leukemic mice.  
 
 
Previous reports suggest that IL10 signaling is a common feature of immune-
suppressive APCs, which may indirectly lead to Treg induction (190, 195).  
Particularly given histology showing that Tregs, leukemic cells, and red pulp 
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macrophages were juxtaposed in close proximity in the red pulp (Figure 3-5), we 
reasoned that IL10 signaling might help induce leukemia-specific Tregs in BCR-
ABL+ B-ALL.  We treated leukemic mice every-third-day with IL10R blockade 
(clone 1B1.3A) or isotype (clone HRPN) and analyzed survival.  We found that 
Il10R blockade treatment did not change overall survival of mice, though formally 
the median survival was slightly increased (Figure 3-16).  However, we also 
found that IL10R blockade did increase BAp:I-Ab-specific T cell count and 
decreased the fraction of BAp:I-Ab-specific T cells that were Tregs (Figure 3-16).  
Importantly, these experiments were not compared to isotype control, but instead 
to historical data. 
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Figure 3-16: IL10 signaling modulates BAp:I-Ab-specific T cell count and phenotype, but 
does not change overall survival in steady-state leukemias. 
A. Naïve, leukemic, or IL10R blockade-treated leukemic mice where harvested and BAp:I-Ab-
specific T cells were enumerated.  Shown is the Log(Y+1) of the BAp:I-Ab-specific T cell count 
from the SLO.  Significance from Kruskal-Wallace and Dunn’s test, all groups contain at least two 
independent experiments.  B. BAp:I-Ab-specific Tregs were analyzed from historical or IL10R 
blockade-treated mice.  Significance from Mann-Whitney U test, both groups contain at least two 
independent experiments.  C. Leukemic mice were treated with IL10R blockade antibody or 
isotype control.  Survival was analyzed by Log-rank (Mantel-Cox) test, at least two independent 
experiments were conducted per-group. 
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Conclusion 
A key question in cancer immunotherapy is whether T cell tolerance can be 
prevented or reversed.  Our findings demonstrate that BCR-ABL specific 
tolerance can be limited by Treg depletion, which correlates with increased 
expression of Ly6C on the BAp:I-Ab-specific T cells.  Ly6C is expressed on Th1-
like effector cells that produce high levels of IFNγ, IL2, and Granzyme B (192).  
Importantly, Th1 cells are classically thought to be critical for tumor control (196).   
Thus our data suggest that LY6C+FOXP3- BAp:I-Ab-specific T cells are useful 
biomarkers of a robust immune response to leukemia (Figure 3-12).  Our data 
also suggests that global excess of Tregs, like that found in Stat5bCA transgenic 
mice, has a negative impact on survival of leukemic mice (Figure 3-11).  It should 
be noted that the Stat5bCA mice have a number of other abnormalities (for 
example, an excess of CD8+ T cells, progenitor B cells, and granulocytes), which 
may impact this analysis (117).  Nonetheless, there is clearly a correlation 
between the excess quantity of Tregs in Stat5bCA mice and decreased survival 
from leukemia seen in this model. 
Depletion of Tregs is not compatible with life, yet leukemic mice with long-term 
Treg depletion survived.  This observation begged the experiment to analyze if 
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the leukemic cells were “rescuing” mice from IPEX that would normally be 
induced in Treg-depleted mice (Figure 3-8).  Indeed, 50% of leukemic, Treg-
depleted mice lived longer than non-leukemic, Treg-depleted mice.  This data 
hints that perhaps leukemic cells have sufficient immune-suppressive functions 
that they can replace Tregs, however further analysis needs to be done.  For 
instance, the only experiments done here are using survival as readout.  Survival 
is probably not the best readout for this experiment since the mice die of different 
pathologies depending on if leukemia is present or absent.  Nonetheless, this 
experiment may be seen as a “jumping-off point” for future studies exploring this 
interesting question. 
In this analysis, we embarked on a number of studies to ascertain the timing of 
leukemia progression relative to Treg induction, and when these Tregs are 
important.  We found that Tregs were important for leukemia progression both at 
early timepoints as well as later during leukemia progression, since Treg 
depletion starting at a late stage of leukemia onset still had a partial impact on 
increasing survival of leukemic mice (Figure 3-10).  Additionally, early depletion 
of Tregs followed by a light, once-weekly DT treatment also led to partial 
increase in survival of leukemic mice, suggesting that strong Treg depletion late 
in leukemia progression also contributed to the survival seen in leukemic 
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Foxp3DTR/DTR mice which received DT every-other-day from leukemia onset until 
morbidity (Figure 3-9).  Taken together, these observations support the 
conclusion that Tregs are required for optimal leukemia progression both at early 
times during leukemia onset and at late times during leukemia progression. 
Our studies clearly demonstrate that Treg induction is an important mechanism 
for suppressing anti-leukemia immune responses. We identified TGFβ1 
production and MHC-II presentation by leukemic cells as key molecular 
mechanisms that allowed conversion of BAp:I-Ab-specific T cells into the Treg 
lineage.  We uncovered leukemic cells and BAp:I-Ab-specific T cells as two 
prominent sources of TGFβ1.  Genetic ablation of MHC-II or antibody-based 
depletion of TGFβ resulted in decreased conversion of BAp:I-Ab-specific T cells 
into Tregs and a corresponding increase in proliferation of BAp:I-Ab-specific T 
cells in response to leukemia.  Thus, our data support the concept that TGFβ1 
and antigen presentation by leukemic cells are critical components in the 
extensive conversion of BAp:I-Ab-specific T cells into the Treg lineage (Figure 
3-14).   
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Temporal regulation of TGFβ1 production by leukemic cells and BAp:I-Ab-specific 
T cells remains to be ascertained in this model.  One likely model is that initial 
TGFβ1 production by the leukemic cells induces BAp:I-Ab-specific Treg 
conversions, which then produce TGFβ1 as well.  In this model, leukemic cell-
derived antigen presentation and TGFβ1 initiate Treg conversion, and BAp:I-Ab-
specific T cell-derived TGFβ1 maintains Treg polarization.  Importantly, such a 
mechanism would allow BAp:I-Ab-specific Tregs to suppress proliferation of other 
anti-leukemia T cells via TGFβ1 (such as GFP:I-Ab-specific T cells in our model).  
 
Regardless of the temporal expression patterns of TGFβ1, the data presented 
herein point to the importance of the leukemia microenvironment. Specifically, 
the leukemia microenvironment has copious amounts of TGFβ, as well as 
antigen presentation by the leukemic cells, which protects the leukemia from the 
host immune response. This model requires leukemic cells to present antigen on 
MHC-II as well as produce TGFβ1, thus suggesting that these two mechanisms 
may synergize to induce immune suppression.  
IL10 signaling has both pro-tumor and anti-tumor roles in other settings (197-
199).  In our model, IL10R blockade (and ostensibly disruption of IL10 signaling) 
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led to appropriate BAp:I-Ab-specific T cell phenotypes (increased expansion of 
the cell population and a decreased fraction of which were Tregs).  However, 
IL10R blockade did not extend survival of leukemic mice (Figure 3-16).  It is 
therefore likely that IL10 signaling has many roles in the immune response to 
BCR-ABL+ B-ALL, and perhaps it plays a detrimental role to the host despite its 
apparent ability to induce canonically better anti-leukemia BAp:I-Ab-specific T 
cells (i.e., more proliferation and a lower fraction that are Foxp3+). 
 
Our findings provide evidence that Treg depletion can modestly extend survival 
of leukemic mice and that this correlates with increased priming and Th1-skewing 
of BAp:I-Ab-specific T cells.  Finally, even though current immunotherapy is 
largely focused on tumor neo-antigens, our studies support the notion that cross-
reactive T cells can play a role in the immune response to leukemia.  Therefore 
our work may inform future therapeutic options which are aimed at reducing the 
number or function of Treg cells present in cancer. 
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Chapter 4 Immunotherapy approaches to treat leukemia: an informed 
approach based on leukemia molecule expression 
Introduction: 
4Patients with B-cell acute lymphoblastic leukemia (B-ALL) harboring the BCR-
ABL chromosomal translocation have very poor outcomes (200, 201).  Current 
therapies for BCR-ABL+ B-ALL include cytotoxic chemotherapeutics, tyrosine 
kinase inhibitors, and bone marrow transplantation.  These treatments are both 
toxic and often transiently effective, indicating that new treatment options are 
urgently needed.  One such option is immunotherapy.  Recent work in cancers 
with high numbers of non-synonymous mutations has demonstrated that 
immunotherapy involving neutralization of PD1 and CTLA4 (checkpoint blockade) 
is an effective treatment option (107, 131-133).  Whether immunotherapy 
involving checkpoint blockade strategies will also be effective in cancers with few 
non-synonymous mutations, such as ALL (109), remains unclear  
                                            
4 The Majority of Chapter 4 has been submitted for publication (Luke Manlove, 
first author) November 2015. 
  109 
 
To determine whether immunotherapy is an effective option for treating B-ALL we 
used a mouse model of BCR-ABL+ B-ALL to characterize the host immune 
response to this leukemia (63, 118, 202).  We found that the host adaptive 
immune system can respond to BCR-ABL+ B-ALL and slow leukemia 
progression.  Although B-ALL cells are believed to have low numbers of non-
synonymous mutations (109), the fusion between BCR and ABL does generate 
an MHC class II restricted peptide antigen that can be recognized by a small 
population of endogenous BAp:I-Ab-specific T cells in mice.  The BAp:I-Ab-
specific T cells were predominately induced to become Treg cells in response to 
leukemia, which suppressed an effective immune response to BCR-ABL+ B-ALL 
(111).  Thus, T cells do respond to BCR-ABL+ leukemia in this mouse model, but 
the response was immune suppressive in nature, and detrimental to host 
survival.   
 
Herein, we address if the immune response to leukemia could be modulated thus 
making BCR-ABL+ B-ALL malleable to checkpoint blockade-based T cell 
immunotherapy.  Three signals are thought to be required to activate a T cell 
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response including (1) peptide:MHC interactions with the T Cell Receptor, ( 2), 
costimulation through CD28, and (3) cytokines and/or costimulatory molecules to 
polarize a response (203-205).  We reasoned that all three signals would need to 
be appropriately aligned for an efficient anti-leukemia T cell response to occur.  
In addressing this issue, we found that mice with BCR-ABL+ B-ALL cells 
expressing high levels of MHC class II, along with a high ratio of the 
costimulatory molecule CD40 relative to the co-inhibitory molecule PDL1, had 
significantly reduced leukemic burden.  We then demonstrated that prophylactic 
vaccination with BAp peptide could induce BAp-specific memory T cells that 
protect mice from BCR-ABL+ B-ALL re-challenge. Thus BAp peptide presentation 
is important for prophylactically generating a protective anti-leukemia immune 
response.   
 
We also wanted to understand if vaccination could be used as a therapeutic 
treatment for leukemia, as opposed to a prophylactic treatment.  Repeated 
immunization of mice with established leukemia with LCMV plus BAp peptide 
(i.e., homologous vaccination) had only a modest effect on overall survival.  In 
contrast, a distinct therapeutic heterologous vaccination involving sequential 
infection with LCMV plus BAp, transgenic LM-BAp and VSV plus BAp led to the 
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generation of a small number of mice that survived long-term.  Antibodies against 
the co-inhibitory molecules (anti-PDL1 and anti-CTLA4) and co-stimulatory 
molecules (anti-CD40) checkpoint blockade had modest effects in a therapeutic 
setting, but when combined with heterologous vaccination significantly enhanced 
long-term survival.  Importantly, this approach did not alter the number of BAp:I-
Ab specific T cells but did significantly alter their cytokine expression pattern.  
Thus, cancers with low numbers of non-synonymous mutations are susceptible 
to checkpoint blockade if combined with an appropriate vaccination strategy 
using leukemia specific antigens.   
Materials and Methods 
Mice 
C57BL/6 mice and Cdkn2a-/-  (strain 01XF6, B6, 129-Cdkn2atm1Cjs/Nci, (113)) 
mice came from the National Cancer Institute.  Foxp3-GFP (stock# 006772) and 
Ifng-/- (stock# 002287) mice came from Jackson Laboratories (Bar Harbor, ME). 
OT-IxRag2-/- mice were generated locally as previously described(116).  Ifng-/- 
and Ifngr-/- mice were obtained Mice were housed at the University of Minnesota 
in specific pathogen free conditions or BSL-2 facilities, and all experiments were 
approved by IACUC. 
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Listeria monocytogenes generation 
Acta- Listeria monocytogenes strain 1942 (from Dr. Sing Sing Way) expressing 
BAp peptide from a plasmid was constructed as previously described (206-208). 
Briefly, the pAM401 vector was digested with PstI and SalI to linearize the vector.  
The digested product was electrophoresed on a 1% agarose gel and purified 
using a Qiagen QiaQuik gel extraction kit (Qiagen, Germantown MD).  BAp 
peptide sequence was synthesized by the BioMedical Genomics Center at the 
University of Minnesota, with a 5’ PstI restriction site and a 3’ SalI restriction site 
(NEB, Ipswich, MA).  The linear pAM401 vector was ligated to the synthesized 
BAp DNA sequence using T4 Ligase (NEB, Ipswich, MA) at room temperature for 
5 minutes.  Ligation reactions were transformed into DH10B Escherichia coli 
(NEB, Ipswich, MA) and plated on plates containing Chloramphenicol (Sigma-
Aldrich, St. Louis, MO).  Colonies were picked and screened by restriction 
digestion with PvuII, HindIII, and BamHI (NEB, Ipswich, MA).  Clones that gave 
the expected restriction digest pattern were sequenced to confirm that they 
contained the appropriate insert.  DNA sequence was translated into peptide 
sequence and aligned to confirm that the BAp peptide was in the same reading 
frame as SIINFEKL (a control peptide in the pAM401 construct).  Correctly 
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assembled clones were electroporated into penicillin-pretreated acta- L. 
monocytogenes strain 1942 at 1500V, 2500 microfarads, and 400 Ohms in 
sucrose-containing media.  Electroporated bacteria were then plated on Brain-
Heart Infusion agar plates supplemented with 20µg/mL chloramphenicol.  Correct 
clones were picked and tested by infection. 
 
 
Infections and Immunizations 
107 Colony-forming Units (CFU) of L. monocytogenes expressing BAp (LM+BAp) 
were injected intravenously through the tailvein (i.v.).  Listeria monocytogenes 
expressing BAp (LM-BAp) or 2W1s peptide  (LM-2W) were grown overnight in 
Brain Heart Infusion supplemented with 20µg/mL chloramphenicol.  The next 
morning, bacteria were then subcultured into fresh Brain Heart Infusion with 
chloramphenicol and analyzed by optical spectrometry at O.D.600 after 4hrs of 
incubation at 37C.  When bacterial cultures reached a density of O.D.600 of 0.5, 
107 Colony-forming Units (CFU) were washed twice in Phosphate-buffered Saline 
(PBS) and injected into mice by tail vein injection in 400µL PBS.  Injections were 
conducted in a BSL-2 facility.  Mice were housed in a BSL-2 facility following 
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infection.  Mice vaccinated with LCMV-Armstrong received 105 plaque forming 
units (pfu) intraperitoneally (i.p.) at day 0. Vesicular Stomatitis Virus-Indiana was 
used at 5x105 pfu i.v. at day 0.  Vaccinia (Western Reserve) was delivered i.v.  At 
day 3 and day 5, mice were injected i.v. with 200µg BAp  Mice were harvested at 
indicated timepoints.  
 
Leukemia model  
The BCR-ABL+ B Acute Lymphoblastic Leukemia model has been previously 
described (118).  Briefly, Cdkn2a-/- mouse bone marrow cells were transduced 
with viral supernatant containing a BCR-ABL (P190)-IRES-GFP retrovirus (119) 
and cultured for adoptive transfer as previously described (63).  
 
Tetramer production 
The BAp:I-Ab tetramer and others used herein were produced as described 
(121).  Purified monomer was tetramerized with SA-PE or SA-APC and cells 
were enriched as previously described (63). 
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In-vivo antibody treatment 
Mice were treated with anti-PDL1 10F.9G2 and anti-CTLA 9H10 (Bio X Cell, 
West Lebanon NH) with 100µg i.p. every-other-day (unvaccinated) and 200µg 
i.p. twice per week (vaccinated).  Mice were treated with anti-CD40 (FGK4.5) 
(Bio X Cell, West Lebanon NH) 200µg i.p. every-other-day.   
 
Antibodies 
Antibodies for flow cytometry and histology include CD3 PE, CD4 (RM4-5) 
PerCPCy5.5, CD8 (53-6.7) BV650, CD11c (N418) PE, FOXP3 (FJK16S) PE, 
CD80 (16-10A1) APC, CD86 (GL1) PE-Cy7, CD19 BV605, B220 (RA3-6B2) 
Horizon V500, IFNγ (XMG1.2) BV650, LAP (TW7-16B4) PE, TNF alpha (MP6-
XT22) BV421, IL17A (TC11-18H10) AlexaFluor488, and PSGL1 (2PH1) BV421 
purchased from BD Biosciences (San Jose, CA); NK1.1 (PK136), CD11b 
(M1/70), CD11c (N418), B220 (RA3-6B2), and F4/80 in APC-eFluor780; PD1 
(J43) FITC, CD73 eFluor450, FR4 PE-Cy7, PDL1 PerCP-eFluor710, MHC-II I-Ab 
eFluor450, IL10 (JESS-16E3) PE, Granzyme B (NGZB) PE-Cy7, GARP 
(YGIC86) eFluor450, and all ELISpot antibodies were purchased from 
eBiosciences (San Diego, CA), and IgM (Fab’) APC was purchased from 
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Jackson Immunoresearch (West Grove, PA).  Rat IgG1 (HRPN) PerCP-Cy5.5 
Isotype and Rat IgG2a (2A3) violetFluor450 Isotype were purchased from Tonbo 
Biosciences (San Diego, CA).  Cells from enriched fractions were analyzed on an 
LSR-II Fortessa cytometer (BD Biosciences, San Jose CA) and data was 
analyzed in FlowJo (Treestar, Ashland OR). 
 
Statistics 
Standard normality tests suggested departures from normality, so non-parametric 
tests (Mann-U Whitney test for two groups, Kruskal-Wallace & Dunns’ Test for 
more than two groups) were used unless otherwise stated.  Normality 
assessments and non-parametric tests were done in GraphPad Prism (LaJolla, 
CA).  Principal component analysis was conducted in R (prcomp function) (209). 
Linear regressions and correlation coefficients were estimated in GraphPad 
Prism and R.   
 
A detailed description of the PCA and corresponding linear regression are 
included herein.  We performed a principal component analysis (PCA) on the 
following five phenotype metrics collected on each mouse: PDL1, MHC-II, CD40, 
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CD80, CD86. We added one to each metric, and then log-transformed the 
resulting value so that our data met the PCA assumption of joint normality. 
Components were estimated using the prcomp function in the stats package in R.  
 
First, pairs plots of the raw manifest variables and log-transformed manifest 
variables were created.  Principal component analysis is a method for reducing 
the dimension of a dataset by transforming an initial set of possibly-correlated 
manifest variables into a set of new, orthogonal variables, which are referred to 
as “components”.  PCA describes the multivariate correlation in the dataset. 
While the method generates as many components as there are measured 
variables in the dataset, most of the variation in the dataset can usually be 
captured with only a few components. Each component consists of a value that 
describes the proportion of variation in the original dataset explained by the 
component, and a set of loadings that describe the extent to which each manifest 
variable correlates with that component. Let  be an  matrix containing 
measurements of k different manifest variables for n sampled individuals. 
Estimation is obtained through an Eigen-decomposition of the square matrix . 
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Eigenvalues correspond to proportions of variance in the original dataset 
captured by each component, and eigenvectors describing correlations between 
each manifest variable and each component. Although the method constructs as 
many principal components as there are manifest variables in the dataset, 
interpretation is limited to those components that explain the preponderance of 
variation in the dataset. The number of components to interpret is often 
determined using a screeplot, showing the proportion of variance explained by 
each component.  
A screeplot for the components identified for the log-transformed immunogenicity 
phenotype metrics is shown in Figure 1D. Based on the screeplot, we interpreted 
the first two components. Each manifest variable's loading on each component is 
shown in Table 1.  
We extracted PC scores for PC1 and PC2 for each mouse in our dataset. We 
used a linear regression model to relate these PC scores to percent leukemic 
burden measured on these same mice. The regression model consisted of four 
terms: an intercept ( ), main effects for each PC, (  and ), and an interaction 
term between the two PCs ( ). Let  be percent leukemic burden in the  
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studied mouse, let  be the  mouse's PC1 score, and let  be the  
mouse's PC2 score. Then the regression model we fit can be written as: 
 
 =  +  ( ) +  ( +  ( ) (   +  
 
The model was fit using the lm function in R (1). An overall F-test clearly 
suggested that at least some of the coefficients in the model differed significantly 
from zero (F-statistic = 23.76 on 3 and 26 degrees of freedom; ). 
Specifically, the model detected strong relationships between the first two PCs 
and leukemic burden, and a marginally significant interaction effect in our 
dataset.  
In general, the intercept term corresponds to expected leukemic burden for mice 
with average scores on both PC1 and PC2. Specifically, under this model we 
expect that mice with average PC1 and PC2 scores have an average leukemic 
burden of 62.64 percent. For mice with an average score of PC2, but who are 
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one unit above average on PC1, we expect an average leukemic burden of 52.64 
percent (62.64 – 10.00). For mice with an average score on PC1, but who are 
one unit about average on PC2, we expect an average leukemic burden of 43.34 
percent (62.64 – 19.30). For mice that are one unit above average on both PC1 
and PC2, we expect an average leukemic burden of 27.38 percent (62.64 – 
10.00 – 19.30 – 5.96).  
 
  Adaptive Immunity: Benefits and Detriments to leukemic 
mouse survival 
We first sought to address the efficacy of the mouse adaptive immune response 
to leukemia in the steady-state (where the only pathogen insult in SPF mice is 
that from BCR-ABL+ leukemia).  Our initial data suggested that leukemia 
progressed faster in OT-I x Rag2-/- mice (Figure 2-3), but we also analyzed the 
survival of these mice when adoptively transferred with leukemic cells (Figure 
4-1).  Contrary to our predictions, we found that OT-I x Rag2-/- mice survived 
longer with leukemia than C57BL/6 mice.  During this analysis, we noticed that 
the way in which the mice became moribund was different between C57BL/6 
hosts and OT-I x Rag2-/- hosts.  Specifically, C57BL/6 hosts uniformly developed 
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bilateral hind-limb paralysis while the OT-I x Rag2-/- developed a broad range of 
leukemia-associated pathologies of which the most prominent was severe 
lymphadenopathy.  Thus, we think that apparent dichotomy between leukemic 
burden and survival is in part due to the endpoints used in the survival analysis. 
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Figure 4-1: Adaptive immunity causes poor survival in steady-state leukemic mice  
OT-I x Rag2-/- hosts (blue line) or C57BL/6 hosts (black line) were adoptively transferred with 
2500 BCR-ABL+ leukemic cells and survival was analyzed.  Log-rank (Mantel-Cox) test was used 
to analyze statistics.  Median survival is also reported. 
 
We also reasoned that adaptive anti-leukemia immunity probably was dependent 
on CD4+ T cells, CD8+ T cells, or both.  To test this, we adoptively transferred 
mice with BCR-ABL+ leukemia and treated with CD4 and/or CD8a depleting 
antibodies at previously published doses (210).  Again, to our surprise, we found 
that none of these depleting regimens had any obvious phenotype as far as 
changing survival of the leukemic mice (Figure 4-2).  From these results, we 
conclude that at steady-state, the T cell compartment of the adaptive immune 
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system is having very little effect on leukemia progression.  Indeed, since we 
know that during this time course a substantial fraction of one leukemia-specific T 
cell population (BAp:I-Ab-specific T cells) are Tregs (Figure 3-2), perhaps the only 
effect that the immune system has on leukemia in steady-state conditions is a 
deleterious one for the host. 
 
CD4+CD8α deplete
Historical 2500 cell
Historical 2500 cell
CD8α deplete
historical 2500 cell tx
CD4 deplete
0
20
40
60
80
100
P
er
ce
nt
 S
ur
vi
va
l
0 20 40 60 80
Time (days)
0
20
40
60
80
100
P
er
ce
nt
 S
ur
vi
va
l
0 20 40 60 80
Time (days)
0
20
40
60
80
100
P
er
ce
nt
 S
ur
vi
va
l
0 20 40 60 80
Time (days)
Median Survival, days
19
CD4+CD8α
deplete
p=ns
Historical 2500 cell 20
Median Survival, days
20
CD8α
deplete
p=ns
Historical 2500 cell 20
Median Survival, days
21
CD4
deplete
p=ns
Historical 2500 cell 20
A B C
 
Figure 4-2: T cell depletion does not change survival of steady-state leukemic mice  
C57BL/6 mice were adoptively transferred with 2500 BCR-ABL+ leukemic cells and survival was 
analyzed.  A. Mice were either untreated (black line) or treated with induction doses of 750µg 
anti-CD4 (GK1.5) and 750µg of anti-CD8 (YTS 169.4) and then followed by weekly doses of 
250µg of the above antibodies for the duration of survival.  B. Mice were treated as in A, except 
with only anti-CD8 being provided (though at the same doses as in A).  C. Mice were treated as in 
A, except with only anti-CD4 being provided (though at the same doses as in A).  All statistics 
come from the Log-rank (Mantel-Cox) test.  Also shown is the median survival. 
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 Antigen presentation and costimulatory markers are expressed in 
certain patterns on leukemic cells 
We previously showed that there was a higher fraction of live leukemic cells in 
the BM and SLO of OT-I x Rag2-/- mice than in C57BL/6 mice.  Further, the range 
of leukemic burdens was quite broad in the C57BL/6 hosts (IQR=11%-69%) but 
less-so in the OT-I x Rag2-/- hosts (IQR=90%-98%) (Figure 2-3:) (63).  To 
understand why there was such a range in leukemic burden, we looked for 
characteristic differences in the leukemic cells from mice with low leukemic 
burden compared to leukemic cells from mice with high leukemic burden.  Since 
B cells can function as antigen presenting cells, we examined the expression of 
MHC-II to stratify the leukemic burden based on expression of surface markers.  
MHC-II expression inversely correlated with leukemic burden (mice that had low 
fraction of leukemic cells in the bone marrow had high MHC-II expression on the 
leukemic cells, Figure 4-3).   
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Figure 4-3: MHC-II expression on leukemic cells in relation to leukemic burden  
Representative dot plots and histograms from five mice with varying leukemic burden (gated as 
live, singlet, CD19+, B220low cells.  Black curves are MHC-II, grey curves are isotype.  Listed are 
the percentages of live singlet events that fall into the CD19+, B220low gate. 
 
Since antigen presentation without any costimulation is ineffective at inducing a T 
cell response, we examined the expression of the costimulatory molecules CD40, 
CD80, CD86, and PDL1.  These costimulatory molecules individually correlated 
with leukemic burden to a minimal degree (Figure 4-4).   
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Figure 4-4: Individual costimulatory molecules have minimal correlative power with 
leukemia progression 
Individual correlations between each contributor to the PCA (CD40, MHC-II, CD86, CD80, and 
PDL1) and leukemic burden-depicted as the percentage of leukemic cells that comprise live cells 
in the bone marrow.  The black line on each graph is the best fit.  Shown also is the r value, r2 
value, and the p-value (from Spearman correlation test).  All correlations, except for that of CD86 
with leukemic burden, are insignificant. 
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Thus, we next sought to identify if there was an ensemble of costimulatory 
molecules that correlated with leukemic burden, by using Principal Components 
Analysis (Figure 4-5).   
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Figure 4-5: PC1 and PC2 account for 77% of variability in leukemia progression  
Screeplots of Principal Components (PC). Y-axis shows proportion of variance accounted for by 
each PC.  Principal component analysis was derived from 27 separate mice in 3 experiments. 
 
The first component described a positive correlation between MHC-II, CD80, 
CD86, and PDL1.  The second component was driven by a negative correlation 
between CD40 and PDL1 (Figure 4-6).   
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Figure 4-6: PC1 and PC2 are defined by distinct costimulation patterns 
Correlations of measured variables with first two principal components.  PDL1, MHC-II, CD80, 
and CD86 correlate positively with PC1; CD40 and (to a lesser extent) CD86 correlate positively, 
while PDL1 correlates negatively, with PC2.   
 
These first two components described 77% of the variation in leukemic burden 
that we observed in mice (Figure 4-7).  
Standard Deviation                1.67      1.05   0.73   0.73    0.26
Proportion of Variance 0.55      0.22   0.11   0.11     0.014
Cumulative Proportion 0.55      0.77   0.88   0.99    1.00
PC1 PC2 PC3 PC4 PC5
 
Figure 4-7: Description of PCs and descriptive power of each PC 
PCs are listed and shown is the standard deviation around each PC, the proportion of variance 
described by each individual PC, and the cumulative proportion of variance described.  
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Figure 4-8: Distribution of individual mouse scores on PCs 1 and 2.   
Mouse leukemic burden is indicated by dot size and dot shade, larger white dots indicate mice 
with higher leukemic burden, and smaller black dots indicate mice with lower leukemic burden. 
 
 
Mice that had low leukemic burden tended to have high scores for both PC1 and 
PC2 (Figure 4-8).  Therefore, we used linear regression to examine relationships 
between the first two PC scores and leukemic burden (Figure 4-9).  Both high 
PC1 and high PC2 scores were associated with significantly decreased leukemic 
burden (p<0.001).  A low PC1 score (score = -2) was predictive of high leukemic 
burden (left panel) regardless of PC2 score.  In contrast, leukemias with higher 
PC1 scores (score = 0-2), showed dependence on PC2 in predicting leukemic 
burden.  These results demonstrate that leukemic burden inversely correlates 
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with the capacity of leukemic cells to activate CD4+ T cells as assessed by MHC-
II, CD40, CD80, CD86, and PDL1 expression on the leukemic cells. 
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Figure 4-9: PC1 and PC2 synergize to predict leukemia progression 
Predicted leukemic burden as a function of PC2 scores at three separate levels of PC1 (low, 
average, and high).  Grey regions denote 95% confidence bounds. 
 
Modulation of individual costimulatory molecules modestly improves 
survival of leukemic mice 
Our PCA suggested that an ensemble of costimulatory molecules (CD80, CD86, 
PDL1, CD40) functioned as a cohesive unit to modulate anti-leukemia immunity.  
Nonetheless, it was possible that individual targeting of antigen presentation and 
costimulatory molecules might change the disease course.  Further, recent 
findings suggest that co-inhibitory molecule blockade is advantageous for 
disease outcome in other cancers (132).  We tested if antibody targeting of 
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PDL1, CTLA4, or CD40 would be sufficient to change leukemia progression.  
Antibody blockade of PDL1 and CTLA4 (either individually, or in combination) led 
to a modest, but significant increase in survival of leukemic mice (Figure 4-10).  
Additionally, treatment of leukemic mice with an anti-CD40 antibody that is 
characterized as an agonist also led to a modest, yet significant increase in 
survival (211) (Figure 4-10).  Thus, the components defined by our PCA do not 
individually identify therapeutic targets in this model, again supporting that these 
molecules must be addressed as an ensemble. 
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Figure 4-10: Individual costimulatory molecule-targeted therapy is only modestly effective 
in BCR-ABL+ B-ALL  
A. C57BL/6 mice were inoculated with 2500 leukemic cells and treated every-other-day with 
100µg anti-PDL1 (clone 10F.9G2) until moribund.  Hazard ratio of 0.10 with a 95% confidence 
interval from 0.025 to 0.42.  B. Mice were treated as in A, except with 100µg anti-CTLA4 (clone 
9H10).  Hazard ratio of 0.21 with a 95% confidence interval from 0.057 to 0.76.  C. Mice were 
treated as in A, except with 100µg anti-PDL1 (clone 10F.9G2) plus 100µg anti-CTLA4 (clone 
9H10).  Hazard ratio of 0.012 with a 95% confidence interval from 0.0018 to 0.18.  D. Mice were 
treated as in A, except with 200µg anti-CD40 (clone FGK4.5).  Hazard ratio of 0.084 with a 95% 
confidence interval from 0.022 to 0.31.  Two or more independent experiments shown in each 
panel, Log-Rank (Mantel-Cox) test was used to establish significance in all panels. 
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BAp-specific T cells can be primed by acute infection plus 
exogenous peptide. 
None of the immune checkpoint modulations we tested yielded substantial 
efficacy at extending survival of leukemic mice.  However, we have previously 
shown that Ly6C+ BAp:I-Ab-specific T cells correlate with anti-leukemia immunity 
upon Treg depletion (63).  We attempted to re-create an inflammatory 
environment by using a variety of pathogen insults to generate many Ly6C+ 
BAp:I-Ab-specific T cells.  We infected mice with Listeria monocytogenes 
expressing the BAp peptide (termed LM+BAp), which caused a 65-fold increase 
in BAp:I-Ab-specific T cell numbers.  In parallel, we infected mice with either 
LCMV-Armstrong, Vaccinia (Western Reserve) or VSV-Indiana and then 
delivered 200µg BAp peptide i.v. at 3 and 5 days post-infection.  This allowed us 
to utilize the inflammation caused by acute viral infection to induce a strong 
BAp:I-Ab-specific CD4+ T cell response (termed LCMV+BAp, Vacc+BAp, or 
VSV+BAp).  At peak infection LCMV+BAp caused a 74-fold proliferation of BAp:I-
Ab-specific T cells, while VSV+BAp caused a 114-fold proliferation of BAp:I-Ab-
specific T cells (Figure 4-11).  These results show that BAp:I-Ab-specific T cell 
proliferation can be initiated by immunization.   
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Figure 4-11: Infection in the presence of BAp yields proliferation of BAp:I-Ab-specific T 
cells  
Naïve mice (N) were immunized with LM+BAp, LCMV+BAp, VSV+BAp or Vaccinia+BAp.  
Secondary lymphoid organs were harvested at peak and BAp:I-Ab-specific T cells were 
enumerated.  More than two independent experiments are shown for each infection.  Kruskal-
Wallace and Dunn’s test used to establish significance.   
 
Additionally we found that LCMV+BAp induced a high frequency of Ly6C+ 
memory BAp:I-Ab-specific T cells following leukemia re-challenge, while LM+BAp 
induced substantially fewer Ly6C+ memory BAp:I-Ab-specific T cells following 
leukemia re-challenge (Figure 4-12).  Since our previous work showed that Ly6C 
was expressed on the majority of BAp-specific T cells upon Treg depletion (which 
also resulted in significantly less leukemic burden and significantly longer survival 
of leukemic mice), we reasoned that acute viral infections were better adjuvants 
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for inducing protective BAp-specific immunity, since they too resulted in a higher 
fraction of BAp-specific T cells expressing Ly6C. 
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Figure 4-12: BAp:I-Ab-specific T cell Ly6C expression following leukemia rechallenge   
Percent Ly6C+ BAp:I-Ab-specific T cells from mice vaccinated with either LM+BAp or LCMV+BAp 
at d0 and then rechallenged with leukemia at d30.  Two or more independent experiments 
conducted for each infection.  Mann-Whitney U Test used to establish significance. 
 
BAp-specific adaptive immunity confers long-term survival for 
leukemic mice. 
The PCA suggested that MHC-II expression, and thus antigen presentation, was 
important in describing the immune response to leukemia.  We have identified 
one peptide from BCR-ABL (BAp) that is processed and presented on MHC-II in 
vivo.  Thus, we hypothesized that immunization with BAp plus strong adjuvants 
cells might mediate protection from BCR-ABL+ B-ALL in mice.  To test this, we 
infected mice with either LCMV-Armstrong (+/- BAp peptide) or VSV-Indiana (+/- 
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BAp peptide) and re-challenged mice with BCR-ABL+ leukemia >40 days later; a 
memory timepoint when no acute inflammation remained. (Figure 4-13).  Only 
mice that were infected with an acute viral pathogen plus BAp peptide exhibited 
long-term survival; mice that were infected with just an acute viral pathogen in 
the absence of BAp succumbed to leukemia rapidly.  Indeed, when comparing all 
vaccinated mice from Figure 4-13, the presence of BAp during the acute viral 
infection was sufficient to drive a hazard ratio of 0.24, suggesting that mice 
vaccinated “+BAp” had a five-fold higher probability of surviving at a given 
timepoint (Figure 4-14).  Thus, BAp-specific adaptive immunity can confer long-
term survival in this model. This evidence supports the conclusion that MHC-II 
antigen presentation of BAp is critical for effective prophylactic vaccination, 
though this analysis provided little functional data for how prophylactic 
vaccination controlled leukemia upon re-challenge. 
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Figure 4-13: Viral prophylactic vaccination with BAp confers long-term survival in some 
leukemic mice  
Prophylactic vaccination with BAp peptide allows long-term survival in leukemic mice.  Mice were 
vaccinated with LCMV-Arm +/- BAp or VSV-I +/- BAp  Greater than 40 days later, mice were 
rechallenged with 2500 BCR-ABL+ leukemic cells and rested until morbidity.  Log-Rank (Mantel-
Cox) test was used to establish significance, three or more independent experiments used for 
each group. 
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Figure 4-14: Presence of BAp during acute infection induces long-term survival of 
leukemic mice 
Vaccinated mice +/- BAp (data taken from experiment depicted in Figure 4-13) were divided into 
two groups strictly based on if the vaccinations included exogenous BAp peptide (+BAp, blue 
line) or did not include exogenous BAp peptide (-BAp, black line).  Significance from Log-rank 
(Mantel-Cox) test.  Hazard ratio, and 95% Confidence Intervals flanking the hazard ratio, are 
shown.   
 
Interferon-γ potentiates anti-leukemia immunity during 
prophylactic vaccination 
Many reports have documented the importance of Interferon-γ (IFNγ) in anti-
tumor immunity (196, 212).  In CD4+ T cells, IFNγ is normally produced by Th1 
cells.  We have previously shown that most BAp:I-Ab-specific T cells responding 
to BCR-ABL+ leukemia at steady-state are Treg cells and thus are likely making 
minimal IFNγ.  Consistent with this idea, we found that the ability of host T cells 
to make IFNγ did not substantially affect survival following inoculation with 
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leukemic cells since Ifng-/- hosts succumbed to leukemia similarly to C57BL/6 
hosts (Figure 4-15).  
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Figure 4-15: IFNγ is not critical for leukemic mouse survival at steady-state 
Naïve C57BL/6 mice or Ifng-/- mice were adoptively transferred with 2500 BCR-ABL+ leukemic 
cells.  Survival was analyzed with the Log-Rank (Mantel-Cox) test used to establish significance.  
Two or more experiments shown for each group.   
 
 
Despite the lack of a clear role for IFNγ at steady-state, we hypothesized that 
IFNγ might play a role in the adaptive immune response to leukemia following 
prophylactic vaccination.  To test this, we prophylactically vaccinated Ifng-/- mice 
with LCMV-Arm+BAp and re-challenged with leukemia at more than 40 days 
post-vaccination.  Survival of vaccinated Ifng-/- host mice was statistically the 
same as that of unvaccinated mice (Figure 4-16).  Comparatively, Ifng-replete 
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mice had long-term survival from LCMV-Arm+BAp vaccination.  Thus, IFNγ 
production was one critical mechanism for effective anti-leukemia immunity 
following prophylactic vaccination. 
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Figure 4-16: IFNγ is required for anti-leukemia immunity after prophylactic vaccination  
Naïve C57BL/6 mice or Ifng-/- mice were vaccinated with LCMV-Armstrong + BAp peptide as in 
Figure 4.  Log-Rank (Mantel-Cox) test used to establish significance.  Two or more independent 
experiments used in each group. 
 
Specific pathogens mediate effective prophylactic vaccination for 
BCR-ABL+ B-ALL. 
Immune memory is a critical component of prophylactic vaccination.  To 
determine if effective BAp:I-Ab-specific memory T cells were formed by 
  140 
vaccination, we infected mice with LM+BAp or LCMV+BAp and waited 40 days to 
enumerate BAp:I-Ab-specific memory T cells.  We recovered significantly more 
memory BAp:I-Ab-specific T cells from LCMV+BAp infected mice than from 
LM+BAp infected mice (Figure 4-17).  We then vaccinated mice with either 
LCMV+BAp or LM+BAp and re-challenged by transferring 2500 leukemic cells 
into the mice 40 days later.  BAp:I-Ab-specific T cell numbers were assessed 14 
days after leukemia re-challenge (i.e., 54 days after initial infection).  Vaccination 
with LCMV+BAp, but not LM+BAp, led to a significant increase in the number of 
BAp:I-Ab-specific T cells following leukemia challenge and decreased leukemic 
burden (4-fold, Figure 4-17, Figure 4-18).  Thus, the increase in BAp:I-Ab memory 
T cell numbers following LCMV+BAp but not LM+BAp vaccination correlated with 
disease outcome. 
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Figure 4-17: BAp:I-Ab-specific T cells form memory and respond to leukemia re-challenge 
A. Mice were infected as in Figure 4-11 and rested 30 days, when BAp:I-Ab-specific T cells 
counts were compared to naïve counts of BAp:I-Ab-specific T cells.  Shown are BAp:I-Ab-specific 
Log (Y+1) T cell counts of BAp:I-Ab-specific memory cells following vaccinations, gated on 
CD11ahighCD44high.  Two or more independent experiments shown for each infection. B. Mice 
were unvaccinated or vaccinated with LCMV+BAp or LM+BAp, and 2500 BCR-ABL+ cells were 
transferred 40 days post-infection.  Shown are BAp:I-Ab-specific Log (Y+1) T cell counts; two or 
more independent experiments shown for each infection.   
 
 
Ly6C denotes effective anti-leukemia CD4+ T cells 
The quality and quantity of BAp:I-Ab-specific memory T cells was different 
comparing LM+BAp vaccination to LCMV+BAp vaccination.  We observed that 
the inter-quartile range of leukemic burdens in the mice vaccinated with 
LCMV+BAp was broad (IQR=1.4 x106, Fig 6C), showing that protection mediated 
by LCMV+BAp vaccination was more effective in some mice than in others.  We 
previously observed that Ly6C expression was increased on BAp:I-Ab-specific T 
cells when Tregs were depleted (63).  Therefore, we examined whether Ly6C 
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expression on BAp:I-Ab-specific T cells correlated with leukemic burden.  Mice 
with high leukemic burden despite prophylactic vaccination (and thus considered 
‘failed vaccinated mice’), had a significantly lower percent of Ly6C+ BAp:I-Ab-
specific T cells than the ‘successfully vaccinated mice’ (Figure 4-18).  
Additionally, significantly more BAp:I-Ab-specific T cells expressed Ly6C after 
LCMV+BAp vaccination (which lowered leukemic burden) than LM+BAp (which 
had no effect on leukemic burden) (Figure 4-12). Importantly, the number of 
Ly6C+ BAp:I-Ab-specific T cells was inversely correlated with leukemic burden in 
LCMV+BAp vaccinated mice.  In contrast, leukemic burden did not correlate with 
total CD4+Ly6C+ cells in these mice (Figure 4-18).  Our data do not directly 
support a causative role for Ly6C+ BAp:I-Ab-specific T cells responding to 
leukemia.  However, our findings do suggest that interaction of leukemia and 
leukemia-specific CD4+ T cells may impact the expression of Ly6C, or that Ly6C+ 
BAp:I-Ab-specific T cells may induce less leukemia progression.  
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Prophylactic vaccination controls the fraction of BAp:I-Ab-specific T 
cells which are induced into the Treg lineage after leukemia 
rechallenge 
We also observed that Treg cells made up a significantly smaller portion of the 
BAp:I-Ab-specific T cell population in mice that were prophylactically vaccinated 
with LCMV+BAp than unvaccinated mice (Figure 4-19).  These results support a 
functional role for Ly6C+FOXP3- BAp:I-Ab-specific T cells during the immune 
response to leukemia following prophylactic vaccination.  
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Figure 4-18: LCMV-Armstrong, but not L. monocytogenes, yields effective prophylactic 
vaccination against leukemia 
A. Mice were treated as in Figure 4-11 and leukemic burden was analyzed.  Lines are median 
values, numbers represent fold changes in median.  B. Percent Ly6C+ on BAp:I-Ab-specific T 
cells harvested from LCMV+BAp-vaccinated mice.  Two or more independent experiments shown 
for each infection.  C. Ly6C+ BAp:I-Ab-specific T cell count negatively correlates with leukemic 
burden from secondary lymphoid organs.  Spearman correlation used to calculate statistical 
significance.  D. Ly6C+CD4+ T cell count does not correlate with leukemic burden from SLO.  
Spearman correlation used to calculate statistical significance. 
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Figure 4-19: Prophylactic LCMV-Arm+BAp vaccination prevents mass-conversion to Treg 
lineage by BAp:I-Ab-specific T cells after leukemia rechallenge 
Foxp3GFP mice were prophylactically vaccinated with LCMV-Arm+BAp and rechallenged with 
2500 BCR-ABL+ leukemic cells >40 days later.  BAp:I-Ab-specific Tregs were enumerated.  
Shown is the fraction of total BAp:I-Ab-specific T cells that were Tregs in the SLO.  
 
Antigen presentation and costimulation on leukemic cells are 
modulated by prophylactic vaccination. 
Our principal component analysis (Figure 4-5) suggests that high ratios of 
CD40:PDL1 and MHC-II:PDL1 may be predictive of low leukemic burden.  We 
examined the leukemic cells from LCMV+BAp vaccinated mice and LM+BAp-
vaccinated mice.  First, we found that leukemias in mice that were successfully 
vaccinated with LCMV+BAp had significantly higher expression of CD40 and 
MHC-II than their “failed vaccination” counterparts (Figure 4-20).   
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Figure 4-20: CD40 and MHC-II expression is higher on leukemic cells from successfully-
vaccinated mice  
A. Mice were vaccinated with LCMV+BAp and inoculated with leukemia 30 days later.  CD40 
Mean Fluorescence Intensity from leukemic cells harvested from Successful vaccinated mice or 
Failed vaccinated mice derived from Figure 6C. Mann-Whitney U Test used to establish 
significance.  B.  MHC-II Mean Fluorescence Intensity from leukemic cells harvested from 
Successful vaccinated mice or Failed Vaccinated mice. Mann-Whitney U test used to establish 
significance. 
 
Second, in fitting with the predictions stemming from our PCA, we found that 
CD40:PDL1 and MHC-II:PDL1 increased on LCMV+BAp vaccinated mice (which 
was an effective vaccination regimen) but not significantly on LM-BAp vaccinated 
mice (an ineffective vaccination regimen, Figure 4-21).  Thus, prophylactic 
vaccination with acute viral pathogens plus BAp peptide results in protection from 
leukemia in correlation with our established biomarkers for leukemia immune 
response.  It is unclear why these same predictors do not apply to LM+BAp 
vaccinated mice.   
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Figure 4-21: CD40, PDL1, and MHC-II follow PCA predictions in leukemias treated with 
viral, but not bacterial, vaccination  
A.  Ratio of Mean Fluorescence Intensity of CD40: PDL1 on leukemic cells was calculated from 
mice vaccinated with LCMV+BAp, and a correlation was calculated between this ratio (X-axis) 
and the log leukemic cell count (Y-axis).  Values from Spearman Correlation.  B.  Ratio of Mean 
Fluorescence Intensity of MHC-II: PDL1 on leukemic cells was calculated from mice vaccinated 
with LCMV+BAp, and a correlation was calculated between this ratio (X-axis) and the log 
leukemic cell count (Y-axis).  Values from Spearman Correlation.  C.  Ratio of Mean 
Fluorescence Intensity of CD40: PDL1 on leukemic cells was calculated from mice vaccinated 
with LM+BAp, and a correlation was calculated between this ratio (X-axis) and the log leukemic 
cell count (Y-axis).  Values from Spearman Correlation.  D. Ratio of Mean Fluorescence Intensity 
of MHC-II: PDL1 on leukemic cells was calculated from mice vaccinated with LM+BAp, and a 
correlation was calculated between this ratio (X-axis) and the log leukemic cell count (Y-axis).  
Values from Spearman Correlation. 
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Therapeutic heterologous vaccination drives long-term survival 
We hypothesized that a pro-inflammatory environment might counter leukemia-
derived immune suppression, while also inducing BAp-specific adaptive 
immunity, and thus inhibit leukemia progression.  To test this hypothesis, we 
therapeutically vaccinated mice, which had established leukemia, using either 
homologous vaccinations with LCMV-Armstrong+BAp peptide or heterologous 
vaccinations with LCMV-Armstrong+BAp, LM+BAp, and VSV-Indiana+BAp 
(Figure 4-22).  Homologous vaccination with LCMV+BAp significantly prolonged 
survival although all mice ultimately succumbed to leukemia.  Heterologous 
vaccination should create a more robust pro-inflammatory response, since 
antibodies created during the primary infection will not neutralize the secondary 
and tertiary infections.  Indeed, heterologous vaccination was significantly more 
effective and led to long-term survival (>twice the median untreated survival) in 
~10% of mice. Thus, repeated vaccination with heterologous agents was an 
effective treatment strategy in mice with BCR-ABL+ B-ALL.   
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Figure 4-22: Therapeutic vaccination confers long-term survival to BCR-ABL+ leukemic 
mice, and synergizes with checkpoint blockade 
Mice were inoculated with 2500 BCR-ABL+ leukemic cells at d0, and then rechallenged with one 
of four different treatments. 1) No treatment (Black); 2) Homologous vaccination with Lymphocytic 
Choriomeningitis Virus (LCMV) Armstrong  at day 7, day 14, and day 21, with 200µg exogenous 
BAp peptide delivered i.v. at three and five days post-infection (days 10, 12, 17, 19, 24, 26) 
(Brown); 3) Heterologous vaccination with LCMV-Armstrong at day 7, LM-BAp at day 14, and 
Vesicular Stomatitis Virus (VSV) Indiana at day 21, with 200µg exogenous BAp peptide delivered 
i.v. at three and five days post-infection (days 10, 12, 17, 19, 24, 26), N=52 (Blue); 4) as in 3, 
except with 200µg of anti-PDL1 (10F.9G2) and 200µg of anti-CTLA4 (9H10) twice per week from 
day 7 to day 80, N=11 (Green).  Surviving mice were euthanized at day 80 post-leukemia 
inoculation.  Shown are survival curves, and the Log-Rank (Mantel-Cox) test was used to analyze 
statistics. 
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The immune response to acute viral and bacterial infection is canonically pro-
inflammatory.  However since the mice have active leukemia, high doses of 
leukemia antigens may still be available during this pro-inflammatory state, which 
may cause chronic antigen stimulation, a situation where PDL1 signaling is highly 
expressed (213).  Additionally, our initial findings showing that CD44 was not 
highly expressed on all BAp:I-Ab-specific T cells responding to leukemia suggest 
that BAp-specific T cell priming is not optimal (63).  CTLA4 blocks interaction of 
CD28 with B7-1 and B7-2 molecules, thereby reducing T cell priming (214).  
Thus, we hypothesized that therapeutically vaccinated mice that were treated 
with dual PDL1/CTLA4 checkpoint blockade might show improved survival.  This 
treatment strategy led to a significant increase in survival beyond that seen for 
either PDL1+CTLA4 blockade (Figure 4-10) or therapeutic vaccination (Figure 
4-22), with 31% of mice surviving long-term.  Since this long-term survival is far 
past the timepoint when inflammation would remain from the therapeutic 
vaccination, it suggests that an adaptive immune response is mediating long-
term survival. 
 
To understand some of the mechanisms allowing effective therapeutic 
vaccination, we compared homologous, heterologous, and heterologous plus 
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checkpoint blockade treatments and assessed BAp:I-Ab-specific T cell expansion 
and effector function.  To do this, we inoculated mice with BCR-ABL+ leukemia 
and started therapeutic vaccination at the same timepoint.  We then harvested 
the mice 21 days later and enumerated BAp:I-Ab-specific T cells.  We found that 
all regimens induced robust proliferation (~1250-fold over naïve precursor 
numbers); however, there was no difference in the number of BAp:I-Ab-specific T 
cells recovered between any of the three treatment groups (Figure 4-23).   
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Figure 4-23: Number of BAp:I-Ab-specific T cells does not correlate with therapeutic 
vaccination outcome  
Mice were treated as in Figure 4-22, but treatment was started on the same day as leukemia 
challenge.  Mice were euthanized at day 21 and BAp:I-Ab-specific T cells were harvested and 
enumerated.  Shown are BAp:I-Ab-specific Log (Y+1) T cell counts; two or more independent 
experiments shown for each infection.  Groups were compared with Kruskal-Wallace and Dunn’s 
test, with no significant differences found. 
 
Since total numbers of BAp:I-Ab-specific T cells did not help give insight into the 
mechanisms that allowed effective therapeutic vaccination, we examined the 
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phenotype of the BAp:I-Ab-specific T cells recovered.  We reasoned that BAp:I-
Ab-specific T cells should take on a more Th1-like phenotype in response to 
therapeutic vaccination, and that this phenotype should correlate with improved 
disease outcome.   
  153 
Het
Grzm B
IFNγ
IL10
IL17
TNFα
Het + CheckptHomologous
844 916 1213
1142 1034 1156
1103 1164 1814
946 1074 1145
5764 4441 5722
BAp:I-Ab-specific T cells
 
Figure 4-24: Cytokine production from BAp:I-Ab-specific T cells during therapeutic 
vaccination 
BAp:I-Ab-specific T cells were harvested from mice as in Figure 8B, and stimulated ex-vivo with 
PMA and Ionomycin to analyze potential cytokine production.  Shown is concatenated data from 
10 individual mice in two or more independent experiments.  The numbers on each histogram are 
the mean fluorescence intensity 
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However, we found no significant increase in IFNγ or TNFα (two canonical Th1 
cytokines).  Interestingly, we found that a larger fraction of BAp:I-Ab-specific T 
cells produced more IL10, Granzyme B, and both IL17 and Granzyme B together 
(Figure 4-24, Figure 4-25), all of which have previously been associated with pro-
inflammatory tumor clearance (93, 197, 215, 216).   
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Figure 4-25: IL10, Granzyme B, and IL17 are produced more in correlation with effective 
therapeutic vaccination 
A. Based on concatenated histograms from Figure 4-24, gates were drawn to delineate “positive” 
vs. “negative” fraction of cells and applied to individual mice.  Percent positive is shown on the Y-
axis for IL10.  Kruskal-Wallace and Dunn’s test used to establish significance. B. Granzyme B 
was analyzed.  Kruskal-Wallace and Dunn’s test used to establish significance. C. Percent of 
BAp:I-Ab-specific T cells which are double-positive for IL17 and Granzyme B is shown and 
analyzed.  Statistics were analyzed by Kruskal-Wallace and Dunn’s test.  D. BAp:I-Ab-specific T 
cells were harvested as in Figure 9A and concatenated events from 10 mice were gated to show 
IL17+, Granzyme B+ percentages of BAp:I-Ab-specific T cells. Numbers on the graph are 
percentage of double-positive events in the gates as shown. 
 
Additionally, we examined expression of PD1, a molecule that is canonically 
associated with anti-inflammatory stimuli.  We found that PD1 expression on 
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BAp:I-Ab-specific T cells positively correlated with leukemic burden in all 
therapeutically vaccinated mice (Figure 4-26), and that PD1 expression was 
lowest on heterologous vaccination plus checkpoint blockade-treated mice.  
Together, these results provide evidence that poly-functional CD4+ leukemia-
specific T cells can produce a combination of IL10, IL17, and Granzyme B, 
correlated with effective anti-leukemia adaptive immunity. 
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Figure 4-26: PD1 expression on BAp:I-Ab-specific T cells decreases as therapeutic 
vaccination efficacy increases 
PD1 expression shown on histograms from concatenated samples receiving either Homologous, 
Heterologous, or Heterologous + Checkpoint Blockade treatment.  PD1 expression on BAp:I-Ab-
specific T cells was analyzed and linear regression was used to compare to leukemic burden in 
the same mouse.  Data from Spearman Correlation shown. 
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Leukemia pathology changes between vaccinated and unvaccinated 
mice 
We also noticed an interesting phenotype change when treating mice with 
vaccination.  For example, in unvaccinated mice, the mice uniformly were 
euthanized when they became moribund from bilateral hind-limb paralysis (a 
phenotype which parallels that previously observed in this model, Richard 
Williams personal communication).  Also, unvaccinated mice had relatively small 
lymph nodes and large spleens (Figure 2-2).  However, in therapeutic 
heterologous vaccinated mice, about fifty percent of the mice developed severe 
lymphadenopathy (morphologically resembling a lymphoma) and displayed no 
signs of hind limb paralysis when they were euthanized.  It is unclear why the 
phenotype changed, but this could suggest that either massive inflammation is 
occurring in the lymph nodes of vaccinated mice (thus resulting in a huge influx 
of immune cells) or that leukemic cells re-localize towards the lymph nodes in 
leukemic mice (thus resulting in a huge influx of leukemic cells).  
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Figure 4-27: Cause of morbidity differs when comparing unvaccinated to vaccinated host 
mice 
Unvaccinated or therapeutic heterologous vaccinated host mice were euthanized following 
IACUC protocols and the gross cause of morbidity was analyzed.  “Leukemia” denotes mice with 
no clearly enlarge lymph nodes and relatively enlarged spleen (see Figure 2-2) and lymphoma 
denotes at least one enlarged lymph node and relatively small spleen.  A. Twenty unvaccinated 
and twenty vaccinated mice were compared.  100% of unvaccinated mice had bilateral hind-limb 
paralysis and 46% of therapeutic heterologous vaccinated mice had bilateral hind-limb paralysis. 
B. Representative spleen and lymph node from one therapeutic heterologous vaccinated mouse 
at the time of morbidity. 
 
 
Discussion 
BCR-ABL+ B-ALL is poorly responsive to current therapies.  One approach that 
has not been well-explored in this disease is checkpoint blockade-based 
immunotherapy.  Checkpoint blockade works well in malignancies with many 
non-synonymous mutations to achieve long-term survival (52, 127, 217-220).  
Presumably, this is because the increased number of non-synonymous 
mutations allows for a concurrent increase in the number of neo-antigen specific 
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T cells.  Comparatively, in cancers with low numbers of non-synonymous 
mutations, like ALL (221), checkpoint blockade-based immunotherapy targeting 
the endogenous immune response is relatively unstudied.  Cancers like ALL 
have fewer non-synonymous mutations, likely resulting in fewer neo-antigen 
specific T cells, and at least some cross-reactive T cells that respond to ALL (63).  
In fact, current paradigms suggest that cancers with low numbers of non-
synonymous mutations are minimally affected by targeting the endogenous 
immune response with checkpoint blockade. Herein, we show that an 
endogenous cross-reactive T cell response can be effective in controlling BCR-
ABL+ B-ALL, but this requires both checkpoint blockade and an aggressive 
heterologous vaccination strategy. 
 
Our data suggests that, at steady-state, a very minimal adaptive immune 
response occurs against leukemia-and any adaptive immune response that 
exists may benefit the leukemia instead of the host.  Supporting this, we saw that 
OT-I xRag2-/- mice actually survived longer with leukemia (albeit with a higher 
leukemic burden) than C57BL/6 mice (Figure 4-1).  This analysis may be 
confounded because OT-I xRag2-/- mice did not develop bilateral hind-limb 
paralysis to the same extent as C57BL/6 mice, but nonetheless this data is worth 
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considering.  Additionally, antibody depletion of CD4+ cells, CD8α+ cells, or both 
in combination, resulted in essentially no change in survival from leukemia 
(though mice in these experiments uniformly succumbed to bilateral hind-limb 
paralysis) (Figure 4-2).  Taken together, these data support the conclusion that 
the steady-state adaptive immune response to BCR-ABL+ leukemia is essentially 
non-existent. 
 
Despite our findings that the steady-state adaptive immune response to leukemia 
was minimal, we found that a strong immune response correlated with decreased 
leukemic burden.  MHC-II expression on leukemic cells correlated with disease 
outcome, which hinted that CD4+ T cells were important for anti-leukemia 
immunity.  We verified a role for MHC-II presentation for one leukemia antigen 
(BAp) by prophylactically vaccinating mice in the presence or absence of BAp 
and analyzing survival.  These experiments (Figure 4-3, Figure 4-13, Figure 
4-14) provide evidence supporting a role for MHC-II mediated presentation of 
BAp in anti-leukemia immunity.  This response requires IFNγ and correlates with 
increased induction of Ly6C on the BAp:I-Ab-specific T cells (Figure 4-16, Figure 
4-18).  Incidentally, prophylactic vaccinations with viral adjuvants that induce 
Type I Interferon (either LCMV-Armstrong or VSV) were more functional than 
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bacterial adjuvants that preferentially induce IL12 (81) (Figure 4-18).  This fits 
with previous clinical findings where Type I Interferon treatment increased the 
survival of some patients with lymphoblastic leukemia (56). 
 
MHC-II expression on leukemic cells (and ostensibly, antigen presentation to 
CD4+ T cells) positively correlated with disease outcome, and this correlation was 
stronger when CD40 was also expressed on leukemic cells.  Conversely, 
leukemic cell expression of PDL1 correlated with worse outcome.  These results 
suggest that both the quantity of antigen presentation (i.e. expression of MHC-II) 
and the quality of antigen presentation (i.e., CD80, and CD86, CD40, and PDL1) 
by leukemic cells dictate anti-leukemia immunity.  We used Principal Component 
Analysis and linear modeling to predict disease outcome of leukemic mice by 
looking at expression patterns of an ensemble of 5 surface molecules related to 
antigen presentation and costimulatory molecules on the leukemic cells (Figure 
4-5).  This analysis highlighted the importance of multiple costimulatory 
molecules on the leukemic cells in disease outcome.  Additionally, this analysis 
strongly suggested a role for targeting the immune checkpoint molecules PDL1 
and CTLA4 as a therapy for BCR-ABL+ B-ALL. 
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Costimulatory and co-inhibitory molecules play a role in cancer progression (71, 
218, 222-226).  In our model we observed statistically significant, yet likely 
biologically irrelevant, increases in survival upon monotherapy with either anti-
PDL1 or anti-CTLA4, or dual checkpoint blockade therapy with both anti-PDL1 
and anti-CTLA4 (Figure 4-10).  Since our leukemia model likely has few non-
synonymous mutations (52, 127), these observations fit the paradigm that large 
numbers of non-synonymous mutations are critical for potent, long-term anti-
tumor immunity. 
 
Immune checkpoint blockade therapy alone was only minimally effective in 
treating leukemic mice in our model.  Thus, we explored therapeutic vaccination 
immunotherapy.  Two lines of evidence precipitated this strategy.  First, previous 
reports show that therapeutic heterologous vaccination can be effective in other 
cancers, albeit in those with higher mutation rates (227).   Second, it was clear 
that MHC-II mediated antigen presentation was important for leukemia outcome, 
and the pathogens used in our therapeutic vaccination scheme all induce MHC-II 
expression on APCs (228-230).  Fittingly, when mice were therapeutically 
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vaccinated with these pro-inflammatory pathogens, we saw increased survival 
(Figure 4-22).  To achieve the most ideal vaccination strategy, we used 
heterologous vaccination.  In this approach, we used multiple infectious 
adjuvants to yield an optimal pro-inflammatory environment for adaptive immune 
activation.  Similar approaches have been used prophylactically (231) and 
therapeutically for cancer (227, 232).  However, our study examines therapeutic 
heterologous vaccination in combination with checkpoint blockade specifically to 
target CD4+ T cells in cancer-an underexplored field. 
 
We observed long-term survival from therapeutic vaccination using a 
heterologous regimen of different infections, but not when using a homologous 
vaccination regimen.  There are multiple possibilities to explain this result.  First, 
oncolytic viruses induce robust anti-tumor immunity, which is improved when 
used in combination with checkpoint blockade (58).  Our therapeutic vaccination 
regimen did include one lytic virus (Vesicular Stomatitis Virus) (216, 233).  Thus, 
the increase in long-term survival we saw with therapeutic heterologous 
vaccination could be due to lytic infection.  However our prophylactic vaccination 
experiments demonstrate that the lytic effect is not critical as both LCMV (a 
lysogenic virus) or VSV (a lytic virus) induced a similar degree of immunity to 
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BCR-ABL+ B-ALL in mice, long after these acute infections would have been 
cleared, arguing against an oncolytic virus mechanism.  Instead, we favor the 
idea that heterologous vaccination induces a cytokine milieu that potently 
activates T cells.  Indeed, our data support this conclusion since BAp:I-Ab-
specific T cells have increased functionality after heterologous vaccination 
(Figure 4-25). 
 
We also showed that therapeutic vaccination synergized with anti-PDL1 and anti-
CTLA4 therapies.  When mice received therapeutic heterologous vaccination in 
combination with anti-PDL1 and anti-CTLA4, 31% had long-term survival, 
compared to 10% for therapeutic heterologous vaccination alone, and 0% for 
anti-PDL1, anti-CTLA4, and anti-PDL1 + anti-CTLA4.  These results suggest that 
even malignancies with few non-synonymous mutations (like B-ALL) can be 
responsive to immunotherapies that classically work well only in malignancies 
with high levels of non-synonymous mutations (52).  Importantly, such results are 
contingent upon aggressive therapeutic vaccination approaches.  One possible 
explanation for this could be that leukemia-derived antigen is available for the 
entire duration of the therapeutic vaccination regimen.  This chronic antigen 
stimulation may lead to further increases in PDL1 and CTLA4 expression on 
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leukemic cells, which may explain the synergy between therapeutic vaccination 
and dual checkpoint blockade. 
 
Our data provide initial mechanistic insights into how therapeutic vaccination 
therapy can lead to leukemia rejection by the C57BL/6 host.  During the 
therapeutic vaccination response, we saw that many BAp:I-Ab-specific T cells 
were poly-functional (producing Granzyme B and multiple cytokines such as 
IFNγ, TNFα, IL10, and IL17).  Importantly, we were able to delineate some 
cytokines that were produced more in the most-effective vaccination regimen 
(therapeutic heterologous vaccination + checkpoint blockade).   With this 
regimen, we saw a significantly increased fraction of BAp:I-Ab-specific T cells that 
produced Granzyme B, IL10 and a combination of Granzyme B + IL17.  This 
observation suggests that effective therapeutic vaccination induces formation of 
poly-functional leukemia-specific CD4+ T cells.  Additionally, we saw a trend 
towards decreased PD1 expression on BAp:I-Ab-specific T cells that correlated 
significantly with decreased leukemic burden (Fig 9A, B).  Previous literature 
supports a potential role of T cell-derived IL10 in anti-tumor immunotherapy (197-
199).  As well, IL17 and Granzyme B have both been implicated in T cell 
responses to cancer (93, 215, 234).  We envision two possibilities for how and 
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when BAp:I-Ab-specific T cells might elicit anti-leukemia immunity after 
therapeutic vaccination.  First, since the most effective therapeutic vaccination 
regimen we used (heterologous vaccination + checkpoint blockade) also yielded 
the greatest fraction of Granzyme B producing BAp:I-Ab-specific T cells, it is 
formally possible that these cells directly kill MHC-II+ BCR-ABL+ leukemic cells.  
Indeed, higher expression of MHC-II on the leukemic cells generally correlates 
with an improved outcome (Figure 4-3).  Second, it is possible these poly-
functional BAp:I-Ab-specific T cells also induce the most potent BAp:I-Ab-specific 
memory T cells, which may be required for long-term leukemia control.  In 
support of this, Th17 cells responding to tumor in other models have a capacity 
for long lifespan, which may be associated with memory formation (93, 235).  
Therefore, our observations provide data supporting that poly-functional BAp:I-
Ab-specific T cells are induced by effective therapeutic vaccination, and that 
these cells go on to help control leukemia. 
 
The current paradigm is that neo-antigen specific T cells have more capacity to 
respond to tumors because the repertoires of these cells have not been impinged 
upon by thymic central tolerance (127).  Implicit in this concept is that cross-
reactive T cells will be less-able to respond to tumors since the repertoires of 
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these cells ostensibly have been limited by thymic central tolerance.  We have 
previously shown multiple lines of evidence that BAp:I-Ab-specific T cells are 
cross-reactive with self antigen and that the BAp:I-Ab-specific T cell repertoire is 
limited by thymic central tolerance (63).  Nonetheless, we observed here that 
BAp-specific adaptive immunity is crucial for anti-leukemia immunity following 
prophylactic vaccination, despite the cross-reactivity of this peptide with self 
antigen. Thus, our observations provide a counterpoint to the idea that neo-
antigen specific T cells are a prerequisite for effective endogenous anti-cancer T 
cell responses (221).  Taken broadly, our observations suggest that fusion 
proteins created by chromosomal translocations may be viable immunotherapy 
targets even when the fusions do not create neo-antigens.  This is particularly 
relevant since chromosomal translocations often result in “driver” mutations, thus 
leaving minimal opportunity for cancer immunoediting to occur.  
 
Checkpoint blockade is thought to work best in tumors with high numbers of non-
synonymous mutations.  Our results support this concept as checkpoint blockade 
was only minimally effective in B-ALL, a leukemia that generally has lower 
numbers of non-synonymous mutations.  Importantly though, we demonstrate 
that aggressive heterologous vaccination synergizes with checkpoint blockade to 
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unmask a strong immune response focused on a well-characterized driver 
mutation (BCR-ABL) that is capable of controlling a highly aggressive and 
uniformly fatal form of leukemia.  Therefore our work establishes immunotherapy 
approaches to induce long-term survival in leukemias like B-ALL that have 
classically been considered refractory to checkpoint blockade-based 
immunotherapy.  
Chapter 5 Conclusions 
We have learned much, but I am still left shaking my head in awe at the amazing 
complexity of living systems.  When working with living systems, it seems that 
nothing can be taken for granted and there may be a surprise around every 
corner.  Indeed, even an “unsurprising” result is hugely satisfying.  The thesis 
project outlined in this document has many interesting results, which I will briefly 
outline below. 
 
We found that a subtle adaptive immune response exists to BCR-ABL+ leukemia 
even in the steady-state (Figure 2-1, Figure 4-1, Figure 4-2).  However, this 
response is complex and is largely mediated by Tregs (Figure 3-1, Figure 3-2) 
that lend a benefit to the leukemia.  A part of this adaptive immune response 
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recognizes a peptide from the BCR-ABL fusion protein (Figure 2-4) and we were 
able to use this fusion peptide (BAp) to construct a peptide: MHC-II tetramer that 
specifically and sensitively labeled BAp:I-Ab-specific T cells (Figure 2-5).  In non-
leukemic, unimmunized mice, the BAp:I-Ab-specific T cells already showed hints 
of having an abnormal repertoire.  Indeed, a small fraction of these cells were 
CD44+, suggesting that some BAp:I-Ab was effectively presented to CD4+ T cells 
in non-leukemic, unimmunized mice (Figure 2-6).  Additionally, the population of 
BAp:I-Ab-specific T cells recovered in these mice was strikingly small (Figure 
2-5), especially when compared to other CD4+ tetramer-binding T cell 
populations enumerated with a similar technique (128).  Additionally, the BAp:I-
Ab-specific T cells proliferated poorly in response to peptide/CFA immunization, 
which is a characteristic that is associated with cross-reactive T cells (Figure 
2-11).  However, in these situations the BAp:I-Ab-specific T cells do express 
surface markers that suggest these cells have experienced cognate peptide: 
MHC-II via the TCR (Figure 2-7).  These lines of evidence all suggest that BAp:I-
Ab-specific T cells are likely cross-reactive with self antigen.  We were able to find 
one probable cross-reactive self antigen in ABL (Figure 2-12) that elicited an 
expansion of BAp:I-Ab tetramer-binding cells upon immunization.  Additionally, it 
seemed that the quantity, but not quality, of BAp:I-Ab-specific T cells was 
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controlled in part through thymic negative selection (Figure 2-13, Figure 2-14, 
Figure 2-15).   
 
Despite a small precursor frequency and phenotypic cross-reactivity, BAp:I-Ab-
specific T cells did respond to BCR-ABL+ (but not BCR-ABL-) leukemia (Figure 
2-8, Figure 2-9).  In this setting, BAp:I-Ab-specific T cells positively correlated with 
leukemic burden, and indeed most of the BAp:I-Ab-specific T cells were induced 
into the Treg lineage in response to leukemia (Figure 3-1, Figure 3-2).  This 
robust induction to the Treg lineage is likely due in part to the cross-reactivity of 
BAp:I-Ab-specific T cells, since a model cross-reactive CD4+ T cell population 
(GFP:I-Ab-specific T cells in a GFP+ host mouse) was also induced into the Treg 
lineage in response to leukemia (Figure 3-3, Figure 3-4). 
 
Tregs were important for allowing leukemia progression in C57BL/6 hosts, as 
Treg depletion in Foxp3DTR/DTR hosts let to significantly increased survival of 
leukemic mice (Figure 3-6).  This correlated with increased numbers of BAp:I-Ab-
specific T cells, increased Th1-like phenotype, and increased antigen 
experiences; suggesting that Tregs were suppression proliferation, polarization, 
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and priming of leukemia-specific T cells at steady-state (Figure 3-12).  
Interestingly, Tregs were likely required for leukemia progression both at initial 
leukemic cell transfer, as well as later during leukemia progression (Figure 3-9, 
Figure 3-10).  This may suggest that Tregs have multiple immune-suppressive 
mechanisms in leukemic mice.  As well, leukemic cells may have a functionally 
immune-suppressive role since leukemic Treg-depleted mice developed less 
IPEX-like pathologies than non-leukemic Treg-depleted mice (Figure 3-8).  
 
In leukemic mice, Tregs, leukemic cells, and red pulp macrophages were all 
located in close proximity in the red pulp of the spleen (Figure 3-5).  This 
environment is canonically immune-suppressive, with red pulp macrophages 
likely producing classic immune-suppressive cytokines TGFβ and IL10.  
Additionally, BAp:I-Ab-specific T cells and leukemic cells produced both of these 
cytokines during the steady-state immune response to leukemia (Figure 3-13).  
Indeed, blockade of either TGFβ or IL10R led to decreased Treg induction 
(Figure 3-14, Figure 3-16) and TGFβ blockade also resulted in increased BAp:I-
Ab-specific T cell numbers during the immune response to leukemia (Figure 
3-14).  Intriguingly, MHC-II expression on leukemic cells was also required for 
efficient Treg induction in correlation with increased survival of MHC-II-/- BCR-
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ABL+ leukemia-bearing mice (Figure 3-14, Figure 3-15).  This result highlights the 
importance of proper antigen presentation in directing an immune response. 
 
In exploring antigen presentation by leukemic cells during the immune response 
to leukemia, we found that a unique expression pattern of MHC-II, CD40, CD80, 
CD86, and PDL1 existed on leukemic cells.  While these variables did not 
individually correlate with leukemic burden (and thus outcome) we were able to 
use Principal Components Analysis to derive components from expression levels 
of these variables (Figure 4-3, Figure 4-4, Figure 4-5, Figure 4-6).  Indeed, high 
levels of MHC-II antigen presentation, along with cells that expressed higher 
CD40 and lower PDL1, correlated with improved disease outcome (Figure 4-9).  
In fact, the first two components of this PCA described 77% of the variability that 
we saw in leukemic burden in our model (Figure 4-7). 
 
This PCA suggested that an entire ensemble of immune-regulatory markers 
would need to be therapeutically targeted to improve disease outcome, and not 
just any one costimulatory or coinhibitory marker individually.  In support of this, 
we found that individual targeting of all the components except MHC-II yielded no 
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biologically relevant change in survival of leukemic mice (Figure 3-15, Figure 
4-10).  However, we also were aware that appropriate antigen presentation and 
costimulation could yield an effective anti-leukemia immune response under 
certain situations.  In support of this, BAp peptide + acute viral prophylactic 
vaccination was sufficient to induce long-term survival of leukemic mice in an 
IFNγ-dependent manner (Figure 4-11, Figure 4-13).  Effective prophylactic 
vaccination was characterized by viral, and not bacterial, prophylactic vaccination 
that produced Ly6C+FOXP3- BAp:I-Ab-specific T cells (Figure 4-12, Figure 4-17, 
Figure 4-18, Figure 4-19, Figure 4-20, Figure 4-21). 
 
While the prophylactic vaccination results were intriguing, we sought to apply this 
to mice that might “come in to the clinic with leukemia”, i.e. in a therapeutic 
setting.  To increase the likelihood of success, we tried a variety of vaccination 
regimens, some of which were based on the idea of heterologous prime-boost.  
In these schemes, we vaccinated mice multiple times with different pathogens at 
each challenge.  Therapeutic heterologous vaccination was effective at inducing 
long-term survival of leukemic mice (Figure 4-22).  Additionally, the checkpoint 
blockade therapies that were minimally effective on their own showed substantial 
synergy with therapeutic heterologous vaccination.  Functionally, our data 
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supports the conclusion that therapeutic heterologous vaccination + checkpoint 
blockade elicits improved outcome by changing the phenotype (and not the 
number) of responding T cells (Figure 4-23, Figure 4-24, Figure 4-25, Figure 
4-26).  Indeed, the most effective vaccination regimens induced BAp:I-Ab-specific 
T cells that produced more variety of cytokines with decreased PD1 expression.  
Finally, we found that the pathology with which leukemic mice present changes if 
mice are vaccinated.  The unvaccinated mice died rapidly and 100% of these 
mice had bilateral hind-limb paralysis associated with minute lymph nodes and 
splenomegaly.  Comparatively, therapeutic heterologous vaccinated mice 
developed severe lymphadenopathy and maintained hind-limb mobility.  It 
remains to be seen what is the cause or effect of this changing phenotype. 
 
This thesis contains some results that, at face-value, appear to be conflicting.  
Namely, MHC-II-/- leukemia allows mice to survive longer than MHC-II replete 
leukemia.  But, MHC-II on leukemic cells positively correlates with improved 
disease outcome.  I think that the explanation for this apparent dichotomy lies in 
comparing “steady-state” leukemic mice versus vaccinated leukemic mice.  My 
theory is that antigen presentation by the leukemic cell is bad for the host (in part 
because of Treg induction).  However, when many more APCs are present (as is 
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the case during the therapeutic vaccinations), the balance is shifted: now 
relatively more of the antigen presentation occurs by non-leukemic cells, and this 
leads to an improved immune response to leukemia. 
 
As I have progressed into writing my thesis, I have gone through many of my 
experimental notes.  Anecdotally, I hypothesized incorrectly 75% of the time.  
And yet, these experiments were still informative, and maybe even more so than 
when I predicted the result!  As I close this chapter of my life, I am struck with 
mixed feelings of melancholy and excitement as I realize that in biology, nothing 
is what you think. Melancholy, because this implies that nothing I did truly 
matters; every “certainty” I found is just evidence for-or-against a theory-and is 
not “certain” at all.  Excitement, because this means that anything can be 
learned.  Thus my thesis, like so many before mine, helps to advance the field by 
providing another perspective.   
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